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Abstract 
Justin Carl Cooley Ph.D 
Ralph N. Adams Institute for Bioanalytical Chemistry 
University of Kansas, 2012 
 
Two methods were developed to evaluate the extent of lipid peroxidation in an 
animal model of focal seizures.  Microdialysis was used to sample from the extracellular 
fluid in specific regions of the hippocampus.  The first method was a CE-fluorescence 
method for the thiobarbituric acid derivatized malondialdehyde (MDA) fluorophore.  The 
second was an HPLC-MS method for seven eicosanoids; five products of the 
cyclooxygenase (COX) pathway (6-ketoprostaglandin F1α, thromboxane B2, 
prostaglandin F2, prostaglandin E2 and prostaglandin D2), one product of the 
lipooxygenase pathway (leukotriene B4), and one free radical byproduct of prostaglandin 
formation (8-isoprostaglandin F2).  In a focal seizure model, a microdialysis probe was 
implanted in either the CA1 or CA3 region of the hippocampus.  The chemical 
convulsant 3-mercaptopropionic acid (3-MPA) was dosed directly into the hippocampus 
by perfusion through the microdialysis probe for 50 minutes to produce a focal seizure.   
 There were significant increases (p > 0.001 compared to control) in MDA from 20 
minutes after the start through 30 minutes after the end of dosing.  It is hypothesized that 
these increases in MDA were related to the COX pathway.  Therefore, an LC-MS 
method was developed and applied to the same animal model.  Interestingly, there were 
decreases in the detectable prostaglandins (E2, D2, F2, and TXB2) during the 3-MPA 
dosing followed by immediate increases after dosing.  It is thought that these 
prostaglandins are rapidly depleted during dosing from excessive oxidative damage. 
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Chapter 1: 
Introduction to Oxidative Stress 
1.1 Oxidative Stress 
1.1.1 Reactive Oxygen Species 
Oxidative stress is the process by which free radicals, in particular reactive oxygen 
species (ROS), react with biological components such as DNA, proteins, and lipids.  
Oxidative stress occurs when high concentrations of ROS lead to an imbalance in the 
redox state of the cell.  ROS such as super oxide and hydrogen peroxide can undergo 
neucleophilic reactions with thiols, amines and polyunsaturated fatty acids (PUFAs) 
found in biological systems.  Super oxide radical (O2
•-) is formed through enzymatic (e.g. 
NADH oxidase) and  nonenzymatic (e.g. ubiquinone) one electron redox reactions [1, 2].  
Superoxide dismutase (SOD) reduces super oxide into hydrogen peroxide and singlet 
oxygen.  Hydrogen peroxide can then be farther reduced to water or react with biological 
electrophiles.  Superoxide can also combine with nitric oxide to form peroxynitrite [3].  
Figure 1.1 shows these biological pathways. 
Transition metal ions also play an important role in radical production.  Metal ions 
(particularly iron) participate in one electron reactions in the Haber-Weiss cycle where 
hydrogen peroxide (or alkyl-hydroperoxide) is catalyzed by the metal ion to produce 
hydroxyl radical (OH•) (or alkyl-O•) [4].  These electron processes are shown in Figure 
1.2.  The continued production of ROS will eventually overwhelm the antioxidant 
defenses of the cell, ultimately causing cellular damage and death.   
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Figure 1.1: Biological pathways of ROS formation leading to cellular damage. 
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Figure 1.2: Reactions involving iron leading to production of ROS.  
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1.1.2 Necrosis/Apoptosis 
 There are two physiological processes leading to cellular death, necrosis and 
apoptosis.  Necrosis is the irreversible loss of metabolic function resulting from injury, 
while apoptosis is programmed cell death resulting in membrane-bound fragments of the 
whole cell containing viable organelles [5].  Necrosis occurs from a direct insult on the 
cell which is the case for an oxidative stress event, such as ischemia/reperfusion or 
seizure.  Apoptosis is initiated through cellular messaging activating the cascade for cell 
death.   
 Cell death is a result of either interference with ATP synthesis or loss in plasma 
membrane function [6].  For example, during ischemia ATP is rapidly depleted due to a 
lack of energy and oxygen getting to the cell.  A drop in ATP production alone does not 
necessarily cause necrosis but can result in acidosis as well as loss in ion homeostasis 
[5, 6].  The changes in cytosolic ion concentrations, particularly Ca2+, can lead to very 
detrimental effects.  Increases in Na+ can lead to cell swelling and, in the case of 
neurons, the inability to produce an action potential, but this damage is reversible.  An 
increase in Ca2+, however, causes an increase in mitochondrial membrane permeability 
leading to a further drop in ATP production and release of reactive oxygen [7].  Calcium 
can come from extracellular influx, release from endoplasmic reticulum, or drop in Ca2+ 
removal [5].  The Ca2+ overload does not solely lead to mitochondrial permeability.  Only 
when in conjunction with the dearth of ATP will Ca2+ cause the permeability transition 
pore to open [7].  Leakage across the mitochondrial membrane from the transition pore 
causes a further decline in ATP production. 
1.1.3 Antioxidants 
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 When free radical species formed outweigh the antioxidant measures major 
cellular damage will occur.  Thiols, particularly glutathione (GSH), play an important role 
in free radical scavenging.  Defense systems that protect against these ROS include 
superoxide dismutase, which converts superoxide into hydrogen peroxide; catalase, 
which catalyzes the reduction of hydrogen peroxide to water and oxygen; and 
glutathione peroxidase, which helps eliminate hydrogen peroxide. 
1.2 Lipid Peroxidation 
1.2.1 Lipid Release and Metabolism 
The brain is highly susceptible to oxidative damage because of its large 
consumption of oxygen, limited antioxidant capacity and high concentration of PUFAs.  
Arachidonic acid (AA) comprises about half of the PUFA phospholipids found in the brain 
[8].  AA is stored in membranes through esterification as phospholipids and is 
enzymatically released by phospholipase A2 [9].  The activity of phospholipase A2 
increases upon the influx of Ca2+ during ischemia or seizure as well as with a drop in pH 
[10].  AA is involved in the synthesis of ceramide (through sphingomyelinase) which 
inhibits the electron transport chain (complex I and II) leading to an increase in hydrogen 
peroxide, generating more ROS [11].  AA can be metabolized by cyclooxygenase 
(COX), forming prostaglandins (PGs); lipooxygenase (LOX), producing leukotrienes and 
hydroperoxyeicosatetraenoic acids; or cytochrome P450, forming epoxyeicosatrienoic 
acids [12].  PGs are synthesized through a 2-step enzymatic oxidation of AA via COX, 
leading to the formation of PGH2 and superoxide [13].  COX-2 (an isoform of COX) is 
highly expressed in glutaminergic neurons and plays a role in neuronal plasticity.  COX-2 
is upregulated by stimuli and cellular stress including that from excitatory amino acids 
[13].   
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Enzymatic reactions make up only a portion of lipid peroxidation; PUFAs are 
highly susceptible to radical attack and oxidation (Figure 1.3).  The C-H bond on a 
methylene group located between two double bonds is weakened, which can easily go 
through hydrogen abstraction creating a carbon radical [4].  The lipid radicals can react 
with oxygen or hydrogen peroxide creating lipid hydroperoxides which can degrade and 
rearrange into short chain aldehydes (e.g. the three carbon dialdehyde, 
malondialdehyde (MDA)) and radical alkenes (Figure 1.3) [14].  Work by Morrow et al. 
revealed that the formation of prostaglandin F2-like compounds formed in vivo resulted 
from non-COX free radical peroxidation of AA and when dosed produced biological 
activity [15].  Clearly both enzymatic and non-enzymatic products of AA metabolism 
should be gauged when studying biological processes associated with lipid peroxidation. 
1.2.2 Lipid Peroxidation Biomarkers 
The subsequent release of AA by PLA2 results in formation of the enzymatic 
products PG and thromboxane, and non-enzymatic lipid peroxidation products 
isoprostane, MDA, 4-hydroxynonenal (4-HNE), and acrolein [16].  Prostaglandins can 
stimulate heme oxygenase to breakdown heme into iron, carbon monoxide and biliverdin 
[17].  Fe2+ is a strong lipid peroxidation agent through Fenton chemistry leading to further 
degradation of PUFAs [4].   
F2-IsoP is one of the most common isoprostane (IsoP) products formed from AA.  
The only difference between IsoPs and PGs is that the chains from the prostane ring in 
IsoP are cis while those of PGs are trans (Figure 1.4 A) [18].  Because of the degree of 
oxidation of the PGs and IsoPs they can easily undergo further degradation to form more 
stable products such as MDA, 4-HNE and acrolein.  MDA formation could also be the 
result of a destructive intermediate in the COX mechanism [19] (Figure 1.4 B).   
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Figure 1.3: Pathway of lipid peroxidation for a PUFA with free radial propagation forming 
MDA along with other aldehydes.  R1 and R2 represent either end of the fatty acid. 
Adapted from [14] 
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Figure 1.4: A) Structural differences between isoprostanes and prostaglandins, note the 
stereochemistry of the chains about the ring.  Shown here are 8-isoprostaglandin F2α 
and prostaglandin F2.  B) Proposed mechanism of MDA formation through prostaglandin 
ring intermediate. 
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B
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1.3 Ischemia/Reperfusion 
1.3.1 Ischemia/Hypoxia 
Ischemia is the deprivation of blood flow to a portion of tissue via arterial 
blockage leading to hypoxia which is a severe (but not complete) drop in cellular oxygen 
[4].  During ischemia ATP is consumed producing hypoxanthine and converting xanthine 
dehydrogenase to xanthine oxidase [20].  The activities of cytochrome oxygenase found 
in the mitochondria are also reduced during ischemia because of the requirement of 
oxygen [21].  This lack of activity from the cytochromes in the mitochondria adds to the 
drop in ATP production.  Cells begin anaerobic metabolism due to the lack of oxygen 
producing lactic acid, abandoning ATP production through the mitochondria.  There is a 
decrease in both glutathione synthesis and reduction of glutathione disulfide during 
hypoxia [22].   
1.3.2 Reperfusion 
A secondary insult of cellular injury occurs during the resurgence of oxygen to 
tissue not damaged from the initial ischemic event.  Upon reperfusion, xanthine oxidase 
catalyzes the production of super oxide and hydrogen peroxide from excess oxygen and 
hypoxanthine [20].  During ischemia the pH of the tissue drops (becoming acidotic) as a 
result of anaerobic glycolysis, while during reperfusion the pH of the hypoxic tissue 
returns to normal (~7).  This phenomenon is known as the pH paradox and causes 
accelerated cell death [23].  However, the absence of oxygen during reperfusion can still 
cause necrosis.  Interestingly, it has been shown that tumor cells which are well-
perfused were hypoxic and had a lower pH than surrounding tissue [24].   A sub-family 
of the epithelial Na+ channels/degenirin, known as the acid-sensing ion channels 
(ASICs) have recently been of interest for studying the effects of the decrease in pH 
10 
 
during ischemia.  The drop in pH causes the ASICs to open, allowing Na+ and Ca2+ into 
the cell [25].  The blocking of ASICs have shown glutamate independent drops in infarct 
volumes and neuroprotection during cerebral ischemia [25, 26].   
It has been shown in vitro that AA metabolites are responsible for the irreversible 
depolarization of neurons after ischemia [27].  AA plays a central role in the increase of 
Ca2+ which has been shown to evoke the release of glutamate in neuronal cells [28, 29].  
This could result in the generation of seizures and epilepsy after ischemia/reperfusion 
injury. 
1.4 Seizure 
1.4.1 Propagation of Neuronal Signal 
 Neurons are specialized cell types which transmit external stimuli from one cell to 
the next through synaptic junctions.  Signal travels through a neuron by polarization of 
the membrane.  This occurs via transmembrane gated ion channels through which Na+, 
K+, Ca2+, and Cl- cross the cell membrane.  Under resting conditions, the neuron is 
considered to be polarized, meaning that the potential difference from inside to outside 
the membrane is negative (about -60 mV) [21].  A stimulus at the synaptic junction will 
cause influx of Na+ or Ca2+ into the dendritic spine of a neuron depolarizing the cell 
membrane about the ion channel, while K+ channel activation prevents the initiation of 
action potential [30].  This localized depolarization (about +30 mV) causes nearby Na+ 
channels to open allowing more Na+ to enter the cell, propagating the signal along the 
neuron.  The direction of the action potential is conserved by the more slowly opened K+ 
channels, however, there is evidence of backpropogation where the action potential 
travels retrogradely toward the dendrite [31].  The efflux of K+ causes the cell membrane 
potential to become more negative to the point of hyperpolarization [32].  The resting 
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potential is then restored by Na+, K+-ATPase pumps.  Figure 1.5 illustrates the 
propagation of signal along an neuronal body and the resulting membrane potentials.   
1.4.2 Excitatory and Inhibitory Mechanisms 
 Seizures occur when there is an imbalance between the excitatory and inhibitory 
mechanisms within the brain.  The initial reasons as to why a seizure event begins are 
unknown, and the aftermath can be quite detrimental to the neurons involved which 
leads to ineffective therapies for patients suffering from epilepsy [33].  Glutamate is the 
most abundant excitatory neurotransmitter and γ-amino butyric acid (GABA) the most 
abundant inhibitory neurotransmitter in the brain [34, 35].  Signal propagation from one 
neuron to the next occurs in the synapse.  When the neuronal signal travels down the 
axon of a neuron and reaches the synapse, the depolarization causes a release of 
vesicular neurotransmitters.  The neurotransmitters cross the synapse to the post-
synaptic neuron (dendritic spine) and elicit a response via transmembrane receptors 
(Figure 1.6).   
Excitation through glutamate release involves glutamate receptors that are either 
G-protein coupled, opening Ca2+ channels, or ionotropic, allowing the influx of Na+ and 
Ca2+ [36].  Such receptors include: N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-
methyl-4-isoxzaole propionate (AMAP), and kainate [37].  Signal inhibition through 
GABA release involves opening of K+ or Cl- channels, causing a repolarization of the 
neuron back to resting potential, stopping signal propagation.  Glutamate is vital for 
signal transmission and neuronal plasticity; however, during prolonged release, 
excitotoxicity occurs causing a continuous neuronal transmission [38].  Cells 
experiencing constant stimuli can undergo apoptosis.   
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Figure 1.5: Propagation of signal along the neuron represented by influx of Na+ and 
efflux of K+ and the membrane potential associated with each.  The slower opening K+ 
channels allow the propagation of signal in one direction.  With permission from [32] 
page s-45. 
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Figure 1.6: Depiction of a synapse with release of neurotransmitters from synaptic 
vesicles  
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1.4.3 Development of Epilepsy 
 The onset of epilepsy is not clearly understood.  Epilepsy is defined as having 
two or more seizure events and affects nearly 3 million people in the US and 50 million 
people worldwide [39].  The majority of epilepsy patients develop symptoms from an 
unknown cause of origin (Table 1.1).  Most common therapeutics used to treat epilepsy 
focus on the inhibitory mechanisms in the brain, either blocking sodium channels or 
increasing GABA synthesis or reuptake [40].  However, because these therapeutics 
merely treat the symptoms and not the underlying cause, upwards of 30% of patients do 
not have remission and anywhere between 12-66% who appear symptom free relapse 
[33].   
1.4.4 Chemically Induced Seizure Models 
 There are a number of chemical seizure models which vary based on the type of 
seizure desired.  There are two fundamental types of seizures; generalized and focal 
[41].  Generalized seizures distribute bilaterally across multiple brain networks.  Focal 
seizures are localized to one specific network and do not cross hemispheres.  To induce 
a generalized seizure, a chemical convulsant is dosed systemically either as a bolus or 
by constant infusion.  A local seizure is produced through a microinjection of the 
convulsant or delivery through a microdialysis probe to the to the specific brain region.  
Details of two seizure models related to this research are described in Chapter 3 of this 
dissertation. 
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Cause Percent of Cases 
Unknown 62 
Stroke 9 
Head Trauma 9 
Alcohol 6 
Neurodegenerative disease 4 
Static Encephalopathy 3.5 
Brain Tumor 3 
 
Table 1.1: Leading causes of epilepsy in the US [42]. 
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1.5 Microdialysis Sampling 
1.5.1 Principles of Microdialysis 
 Microdialysis is a diffusion-based sampling technique.  Microdialysis sampling 
involves the implantation of a semipermeable membrane into a target tissue with 
perfusion of an isotonic solution [43, 44].  Small molecules in the extracellular space will 
diffuse across the membrane due to the concentration gradient and are then carried out 
by the perfusion solution and collected as dialysate (Figure 1.7).  The perfusion solution 
is prepared to match the electrolyte composition (e.g. Ringer’s solution, artificial cerebral 
spinal fluid (aCSF), etc.) of the tissue being studied.  This is done to prevent a net 
exchange of water across the membrane keeping the volume of the tissue constant.  
Samples are collected over a specific period of time determined by the desired temporal 
resolution.  Microdialysis provides clean, protein free samples without the strenuous 
workup required for tissue homogenates [45]; however, the samples are of high salt 
concentration and usually low volumes (µl).   
The flow rate of the perfusate and length of membrane play a particularly 
important role in the extraction efficiency (EE) of analytes.  EE is proportional to the 
concentration gradient across the membrane and can be determined by the ratio of the 
concentration in the dialysate to that in the sample/tissue [46].  EE is determined based 
on the following equation:  
   
     
     
                   
were Cs is the concentration in the sample (e.g. brain ECF), Cp is the concentration in 
the perfusate, and Cd is the concentration in the dialysate [47].   
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Figure 1.7: Diagram of a linear microdialysis probe.  As demonstrated, small molecules 
are able to diffuse across the membrane and be collected as dialysate while 
macromolecules such as proteins remain in the extracellular space.   
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At low flow rates (0.1 µl/min) EE goes up; however, temporal resolution must be 
sacrificed in order to collect enough volume of sample [48].  The opposite is true for high 
flow rates.  Microdialysis also provides the advantage of delivering chemicals to the site 
of implantation while collecting samples simultaneously.  Delivery of a known analyte 
can be used to determine EE and probe calibration.  The overall relative recovery (RR) 
for an endogenous chemical can be calculated by: 
   
  
  
                       
however, the Cs cannot be determined without performing calibration experiments [47, 
49]. 
1.5.2 Microdialysis Calibration 
 Microdialysis is a continual flow technique; therefore, equilibrium for compounds 
between the extracellular space and across the membrane is not achieved at relevant 
flow rates or membrane lengths [44].  In order to accurately evaluate in vivo 
concentrations EE needs to be determined through probe calibration.  The most 
common in vivo calibration method is the no-net flux (NNF) experiment where varying 
concentrations of the analyte of interest are perfused.  A graph of (Cp-Cd) vs. Cp is 
constructed where the EE is the negative of the slope of a linear regression line and Cs 
is the x-intercept [47, 50].  The NNF can easily determine if recovery across the 
membrane is dependent on concentration.  However, the NNF experiment is very time 
consuming, taking up to 8 hours (five perfusion concentration with 50 minute collection 
periods plus re-equilibration between).   
 Calibration can also be performed by constant delivery, also known as 
retrodialysis.  In this case, the calibrant is perfused for the entire experiment [47].  The 
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equation for calculating delivery (D) is similar to equation (1) except here, Cs equals 
zero: 
  
     
  
                   
The assumption here is that the delivery and recovery of an analyte are equal across 
both directions of the probe [51].  The difficulty, however, is finding a calibrant that is 
chemically similar to the biomarker of interest without inducing a biological response.  
Therefore retrodialysis is usually performed using compounds which have limited 
biological activity (e.g. Adriamycin), and it is the relative changes in probe performance 
which are monitored during the experiment and on the exact delivery. 
 Another form of retrodialysis can be performed using the analyte of interest as 
the calibrant.  This technique involves perfusing the analyte before and after the 
experiment, and if the EE is the same then it is assumed the probe performance was 
maintained throughout the experiment [51].  Of course an allotted amount of time before 
the experiment is required to not only perfuse the analyte long enough to calculate EE, 
but also to allow the complete flushing and clearing as to not skew the results.  This 
technique can be troublesome if the analyte causes a biological response when dosed 
and therefore great care needs to be taken when interpreting results. 
1.5.3 Advantages/Disadvantages of Microdialysis 
 Microdialysis offers excellent selectivity with regards to sampling, providing site 
specific, real time samples which are protein free.  Microdialysis probes have been 
implanted in virtually every organ in the body.  By implanting probes in selected regions, 
biological processes happening at the site of incidence can be monitored.  This cannot 
be accomplished by sampling blood or urine.  Microdialysis is a continuous sampling 
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technique, which allows for collection of basal samples prior to and after perturbation of 
a system.  Each experiment not only acts as its own control, but also provides the 
temporal resolution and lowered variability (animal to animal) that tissue harvesting 
cannot accomplish [52].  The molecular weight cutoff (MWC) for membranes can range 
anywhere from 5 to 100 kDa.  This MWC range affords experimental design to be more 
selective with protein extraction than tissue harvesting.   
However, microdialysis sampling has many limitations such as sample volume, 
sample matrix composition, and analyte recovery.  Because microdialysis is a diffusion 
based technique, the sample volume collected is limited to the extraction efficiency of 
the analyte of interest.  If the analyte has low EE, then flow rate should be decreased in 
order to improve recovery, however, a slower flow rate leads to small collection volumes.  
Sample volumes can be increased by increasing sampling time but with a sacrifice in 
temporal resolution.  Other in vivo monitoring techniques such as biosensors or 
electrochemical voltammetry can provide better temporal and spatial resolution than 
microdialysis.  However, their selectivity limits them to analytes that are either enzyme 
specific (i.e. glucose) or electroactive (i.e. dopamine) [53, 54].  Microdialysis is more 
conducive to the range of biomarkers to be studied here. 
1.5.4 Analytical Considerations When Using Microdialysis 
 A good analytical technique for use with microdialysis samples should have the 
following characteristics: 1) be robust, 2) have short analysis times, 3) be compatible 
with high salt matrices, and 4) require small volumes.  The most common analytical 
techniques used for microdialysis samples are separation based techniques (HPLC or 
CE) coupled to a general detection method (UV/vis, fluorescence, electrochemical or 
mass spectrometry).  These methods are well suited for microdialysis samples because 
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they do not require large volumes and have throughput on the minute time scale.  
However, when developing a method it is important to not only consider the sample 
matrix but the volume required as well.   
In microdialysis, sample volume is inversely proportional to temporal resolution.  
If the analytical method requires 5 µl of sample, then sampling and/or flow rate must be 
sufficient to meet this need.  For instance, if drug A has a half-life of 2 minutes, then the 
sampling rate must be 1 minute or less in order to have enough data points for 
pharmacokinetic studies.  A common microdialysis flow rate of 1 µL/min would allow a 
maximum of 1 µL for analysis.  If the microdialysis flow rate must be increased to meet 
the volume requirements and temporal resolution, then there will be a sacrifice in the EE 
of the analyte. 
1.6 Conclusions 
 Lipid peroxidation is involved in multiple cellular processes during oxidative 
stress events.  The purpose of this research project was to develop methods to detect 
biomarkers of lipid peroxidation, specifically, MDA and eicosanoids (PGF2, PGE2, PGD2, 
LTB4, 6-keto-PGF1α, TXB2, and 8-iso-PGF2α), and to apply these methods to evaluate 
their formation in vivo.  Microdialysis was used to sample the extracellular fluid in animal 
models of induced oxidative stress.  The goal of this work is to aid in the understanding 
of the molecular mechanisms associated with lipid degradation during a chemically 
induced model of epilepsy.   
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Chapter 2: 
Capillary Electrophoresis-Fluorescence Method for Malondialdehyde 
Introduction 
 Malondialdehyde (MDA) is a three carbon dialdehyde produced as a secondary 
product of lipid peroxidation.  MDA was originally studied in the late 1950’s as a measure 
of food rancidity [1, 2] but recently has become viewed as a biomarker for lipid 
peroxidation [3].  During oxidative stress, polyunsaturated fatty acids can be attacked by 
ROS to form lipid hydroperoxides which readily decompose to form secondary products 
such as MDA, 4-hydroxynonenal, and dienals [4, 5].  MDA is used as a reliable 
biomarker to determine the extent of lipid peroxidation [6-8].  Although MDA absorbs at 
245 nm and 267 nm in acidic and basic solutions respectively, the most common method 
for detection is by derivatization to produce a fluorophore, in particular through the 
thiobarbituric acid (TBA) assay (for review see Janero [3] and Grotto [9]).  Briefly, TBA 
reacts with MDA in a 2:1 ratio in acidic media and at high temperatures to form a pink 
product which absorbs at 530 nm and emits at 550 nm.  It should be noted, however, 
that the TBA assay is not specific for MDA and will react with dialdehydes and 
pyrimidines producing similar absorbance spectra [10].  However, MDA is comparatively 
more reactive and has greater fluorescence intensity than other TBA products per molar 
ratio [11].  Therefore, coupling fluorescence detection with a separation technique must 
be employed in order to increase selectivity and more accurately quantify MDA.   
MDA has been studied in such matrixes as plasma [12, 13], breath condensate 
[14] and tissue homogenate [15, 16]; in conjunction with separation techniques such as 
HPLC-UV/fluorescence [16-19] GC-MS [20], and CE-UV/fluorescence [12, 13, 19].  
Although MDA has been monitored previously in microdialysis samples using HPLC 
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methods [21, 22], the sample volume required greatly limited the temporal resolution 
during animal experimentation.  In this chapter the development of a CE-fluorescence 
method for the detection of MDA in microdialysis samples through derivatization with the 
TBA assay is described. 
2.1 Capillary Electrophoresis 
2.1.1 Basic Principles  
 Capillary electrophoresis (CE) is a separation method in which a potential is 
applied across a fused silica capillary containing a conducting solution (background 
electrolyte (BGE)) and analytes are separated based on their electrophoretic mobility (a 
function of their hydrodynamic radius and charge).  Two factors affect the direction and 
velocity of analytes in CE, migration of the ion µ ion and electroosmotic flow (EOF) µ EOF.  
The sum of these two vectors along with the electric field strength E determines the total 
migration velocity of the analyte given by  
     
  
 
                  
where v is the velocity, µ is the electrophoretic mobility, E is the electric field strength, V 
is the applied voltage and L is the length of the capillary [23, 24].  Electrophoretic 
mobility is limited by the frictional forces of the medium as described by 
  
 
    
                   
were q is the ion charge, r is the solvated radius, and η is the viscosity of the solution 
[25].  Note the denominator is the frictional coefficient from Stokes’ Law.  If no EOF was 
present, all charged analytes would migrate toward their respective counter electrode 
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(cations to the cathode, anions to the anode) and neutrals would remain stationary.  
EOF is the driving force for all species to migrate in a unilateral direction.    
EOF is a result of the interaction of the solution with the surface wall of the 
capillary [24].  At basic pHs the silanol groups on the surface of the capillary will become 
negatively charged at which point cations in solution will attract to it creating a double 
layer, consisting of a fixed and mobile layer [26].  Under normal polarity conditions, 
where the outlet is the cathode, the cations in the mobile layer will migrate toward the 
outlet pulling bulk solution with them creating EOF (Figure 2.1).  The magnitude of the 
EOF is dependent on the pH of the BGE as determined by the deprotonation of silanol 
groups along the capillary wall [26].  At higher pHs the EOF will have a greater 
magnitude than most other species creating a net migration toward the outlet where the 
detector is situated.   
 CE however, is ineffective at separating neutral compounds which will simply 
migrate with the EOF.  To resolve this issue surfactants are added to the BGE in order to 
create a secondary mode of separation at concentrations above their critical micelle 
concentration (CMC) [27].  These micelles will migrate toward the outlet but at a different 
rate than the EOF [28].  Neutral analytes will partition in and out of the micelle based on 
their hydrophobicity giving them a net mobility between that of the EOF and micelles.  
This type of separation is termed micellar electrokinetic chromatography (MEKC).   
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Figure 2.1: Representation of the fixed and mobile layers in CE separation along with 
characteristic migration vectors for anions, cations and EOF.  The EOF migration vector 
is greater in magnitude than the anion vectors providing a total vector towards the outlet 
(detector). 
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2.1.2 CE Detection Methods 
 The detector is attached to the capillary at the outlet end, usually the cathode, in 
which the buffer solution will create an EOF toward the cathode and pull all species 
(positive, neutral, and negative) in that direction.  Several types of detectors can be used 
depending on the analyte of interest; absorbance, fluorescence, electrochemical, or 
mass spectrometric.   
UV/Vis spectrophotometric detection is simple and relatively inexpensive to use, 
and because of its nondestructive characteristics, it can easily be used in tandem with 
other detectors [29].  A spectrophotometric UV detector for CE has the same 
components as those used in HPLC.  A major limitation to using UV detectors, however, 
is in the detection cell.  Since the path length is no more than 100 µm, the capillary has 
to be manipulated/bent at the detector window in order to improve detection limits [30].   
Fluorescence detection is considered one of the most sensitive detection 
techniques used for CE, particularly laser-induced fluorescence (LIF) capable of 
detection on the nM and subnanomolar scale.  Several designs for LIF detector units are 
available one of which is the “ball lens” Picometrics arrangement [29].  Fluorescence is a 
very attractive detection setup for CE because the signal (emission) is determined, in 
part, by the intensity of excitation source making the use of lasers extremely 
advantageous.  The major pitfall, however, is the ability to match the laser wavelength 
with the excitation wavelength of the analyte or fluorophore, greatly limiting the variety of 
derivatizing agents applicable to CE-LIF. 
With the small flow rates associated with CE it would be effective to integrate 
mass spectrometric detectors to the end of a capillary due to their high selective and 
sensitive analysis.  The coupling of CE and MS, however, is more complicated than 
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coupling with LC [31].  Because CE produces a high background current (associated 
with the separation voltage) and has such low flow rates, it cannot be directly coupled 
into the MS.  To circumvent the high CE current, a terminating voltage is indirectly 
applied to the buffer leaving the capillary by using a sheath liquid [29, 31].  The sheath 
liquid merges with CE effluent along with a nebulizing gas to facilitate ESI prior to MS 
analysis. 
2.1.3 CE with Microdialysis Samples 
 The major difficulty when analyzing microdialysis samples with CE is the vast 
difference in conductance between the sample and the BGE.  Most CE buffers are at 
concentrations in the low mM range (10-40 mM); however, microdialysis samples have a 
salt concentration of about 150 mM.  When voltage is applied across the capillary, there 
is a drop in field strength across the sample plug due to high conductance.  This results 
in analytes migrating faster once they cross the sample/BGE boundary causing 
destacking (peak broadening).    
Using micelles for sweeping in CE is ideal when the sample matrix is of low 
conductivity and the analytes are relatively hydrophobic [32].  However, this does not 
mean that the addition of micelles is only useful for separation purposes.  Landers et al. 
described how micelles will stack at the detector side of an injection plug when the 
sample matrix is of higher conductivity than the BGE [33].  In this instance, the micelles 
stack because of the decrease in electric field at the sample plug.  Essentially, field 
amplification occurs in the buffer and not in the sample zone.  Analytes will stack at the 
sample/micelle boundary as a result of the reduced velocity from the high micelle 
concentration. 
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2.2 Method 
2.2.1 Chemicals 
MDA (malondialdehyde tetrabutylammonium salt), boric acid, 3-
mercaptopropionic acid (3-MPA) and TBA were purchased from Sigma-Aldrich (St. 
Louis, MO).  TBA was also purchased from Cayman Chemical (Ann Arbor, MI).  Brij 35 
was purchased from MP Biomedicals (Solon, OH).  Sulfuric acid and salts for Ringer’s 
solution were purchased from Fisher (Fair Lawn, NJ).  Ringer’s solution composition 
was: 147 mM NaCl, 3 mM KCl, 1 mM MgCl2, and 1.2 mM CaCl2.  All solutions were 
made using nanopure water obtained from a Labconco Water Pro Plus purification 
system (Kansas City, KS). 
2.2.2 Reaction Conditions 
 All MDA standards were made in Ringer’s solution.  TBA was made fresh daily at 
a concentration of 0.4% (w/v) in nanopure water.  TBA was dissolved using a stir bar in a 
scintillation vial.  Sulfuric acid was diluted with nanopure water to a concentration of 
0.4% (v/v) and could be used for several months.  For the reaction, an MDA:TBA:acid 
ratio of 8:2:1 was used.  TBA and sulfuric acid were mixed (60:30) and 3 µL of that 
mixture was added to 8 µL of MDA standard or sample in a 200 µL microcentrifuge tube.  
TBA and sulfuric acid were pre-mixed to reduce pipetting error.  The reaction mixture 
was vortex for ~3 seconds then placed in a 90-95°C water bath for 20 minutes.  After 
heating, the standards/samples were immediately placed in liquid nitrogen for flash 
freezing then stored at -80°C until used.   
2.2.3 CE Method 
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 MDA was separated by capillary electrophoresis with fluorescence detection.  A 
75 µm inner diameter (ID) capillary was cut to 55 cm total length and a window of about 
2 mm in length was burned at the middle of the 45 cm mark.  The background electrolyte 
(BGE) was a 200 mM boric acid solution with 4.5 mM brij 35 adjusted to pH 8.4 with 
NaOH.  The capillary was flushed between runs with methanol (2 min), NaOH (2 min) 
and BGE (3 min) at 20 psi each.  Prior to injection, the derivatized standard/sample was 
removed from the freezer and allowed to warm to room temperature for about 5 min and 
vortexed for about 5 sec.  Any water adhered to the lid of the microcentrifuge tube was 
pipetted back to the mixture using a micropipette and re-vortexed.  The solution was 
hydrodynamically injected with 0.5 psi for 5 seconds and the separation voltage was set 
at 10 kV.  It should be noted that since a hydrodynamic injection method is being used, it 
was important to ensure the inlet of the capillary was cut straight.  A jagged end at the 
inlet will lead to peak tailing.   
The separation was performed on a Beckman Coulter P/ACE MDQ CE system 
with a 488 nm Laser Module as the excitation source and a 560 nm band pass emission 
filter.  The data were collected and analyzed using 32-Karat software.  The gain of the 
instrument could be adjusted by changing the range setting in the 32-Karat software.  
The range was set at 100 for all experiments.  This setting prevented peak plateauing 
from high MDA concentrations at a low range (10) and limited noise associated with a 
high range (1000).  The Calibration Correction Factor (CCF) could also be slightly 
adjusted to give optimal S/N; here it was set a 1. 
2.2.4 Mass Spectrometry 
 To identify an unknown contaminate, a blank and standard solutions were 
analyzed using flow injection mass spectrometry.  The same reaction conditions as 
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mentioned above were used, but scaled up 50 times.  After derivatization, the 10 µM 
MDA-TBA standard and TBA blank were extracted using n-butanol to remove salt and 
sulfuric acid which are detrimental to the mass spectrometer.  Other organic solvents 
such as ethyl acetate and hexanes were unable to extract the TBA-MDA fluorophore.  
Three 200 µL aliquots were used for extraction and the butanol was evaporated under 
argon stream.  The dried extracts were reconstituted with 50:50 methanol:water.  The 
butanol extracted constituents from both a blank and MDA standard were analyzed by 
collision induced dissociation in a linear ion trap (Thermo LTQ XL) using ESI in negative 
ion mode with syringe pump flow injection at 2 µL/min.   
2.2.5 Microdialysis Probe Fabrication 
Microdialysis probes were implanted into multiple tissue sites to help validate the 
application of the MDA method.  For liver, heart, and muscle implantation, 
polyacrylonitrile (PAN) membrane (Hospal, Lakewood, CO) of dimensions 350 µm outer 
diameter (OD) and 260 µm ID with a molecular weight cutoff of 20 kDa was used as the 
microdialysis window.  The PAN membrane was cut and attached using UV curing glue 
to two strips of polyimide tubing (MicroLumen, Tampa, FL) of dimensions 160 µm OD 
and 120 µm ID.  A 2 cm piece of Tygon tubing was attached to the inlet tube in order to 
affix the probe to a syringe.  The probe window was 10 mm for liver and muscle and 2 
mm for heart.  For brain implantation, a CMA 12 Elite (CMA, N. Chelmsford, MA) 2 mm 
probe with a cutoff of 20 kDa was implanted into the hippocampus at coordinates -3.3 
A/P, +1.7 L/M, -3.7 D/V reference from bregma line. 
2.2.6 Liver Animal Model 
 Male Sprague Dawley rats were anesthetized with isoflurane followed by a 
subcutaneous injection of ketamine/xylazine/acepromazine mixture (67.5 / 3.4 / 0.67 
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mg/kg respectively).  The animal’s stomach was shaved and a midline incision was 
made below the sternum opening the abdominal cavity.  Adjustable retractors were used 
to hold the cavity open during surgery.  A 23 gauge needle was inserted in to the left 
liver lobe to guide the microdialysis probe in place.  The needle was removed and tissue 
glue was applied to secure the probe.  Ischemia was produced by securing a set of 
tissue forceps around left hepatic artery for 30 minutes.  All animal experiments were 
performed in accordance with the local Institutional Animal Care and Use Committee 
(IACUC) and follow the principles stated in the Guide for the Care and Use of Laboratory 
Animals (National Academy of Sciences, 1996).  All chemical solutions used for 
microdialysis experiments were diluted in Ringer’s solution.  The probe was perfused for 
a 1 hour recovery period before basal sample collection was started.  Samples were 
collected over a 10 minute interval with a perfusion rate of 1 µL/min. 
2.2.7 Antipyrine LC-UV Method 
 Antipyrine was detected at 241 nm using an LC-UV system (Shimadzu LC-10AD 
pump and SPD-10A UV/Vis detector).  Liver samples (1 µL) were injected onto a 
Phenomenex Synergy Polar-RP (150 x 2 mm, 4 µm) column with a mobile phase of 25 
mM acetic acid with 17% ACN (v/v).  The pH was adjusted to 4.5 using NaOH and flow 
rate was set at 0.300 mL/min. 
2.3 Discussion 
2.3.1 Reaction 
Although MDA absorbs at 245 and 267 nm in acidic and basic media respectively 
it has relatively low absorptivity [3].  MDA reacts with TBA in a neucliophilic 
condensation type reaction where one molecule of MDA reacts with two molecules of 
TBA.  This product produces a fluorophore with excitation at 530 nm and emission at 
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560 nm (Figure 2.2).  Varying concentrations of sulfuric acid provided no observable 
changes in peak area; however, a noticeable difference in sensitivity could be seen at 
lower concentrations of TBA.  The majority of TBA methods call for 0.4-0.5 % TBA [3, 
34]; however, in an attempt to reduce an observed TBA contaminant, the TBA 
concentration was decreased.  With a decrease in the TBA concentration to 0.1%, the 
sensitivity only decreased by 0.5 and y-intercept by 2.5.  Because the degree of MDA 
production resulting from oxidative stresses in vivo remained unclear, it would be more 
advantageous to use 0.4% TBA and have the added sensitivity even though the 
contaminant in the blank TBA decreased with lower concentrations.   
 The 20 minute reaction time was also examined.  When a large volume of 
reaction mixture was used and aliquots were taken at specific time points, maximum 
peak intensity was achieved at around 60 minutes.  However, calibration curves made at 
longer reaction times with low volume solutions were non-linear particularly at low MDA 
concentrations.  At low volumes, water evaporates and condenses on the lid of the 
microcentrifuge tube, leaving a heavily salted solution changing reaction kinetics.  The 
longer reaction times also had a larger contribution from the TBA impurity (Figure 2.3).  
A reaction time of 20 minutes, although not ideal, provided the most reproducible and 
linear standard curves.  A 20 minute reaction time also had the largest difference 
between MDA-TBA and the TBA contaminant (Figure 2.3). 
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Figure 2.2: Derivatization scheme of MDA with 2 molecules of TBA. Fluorescence 
excitation and emission spectra showing maximum excitation at 530 nm and emission at 
550 nm. With permission from [35] 
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Figure 2.3:  Graph of normalized peak height for the TBA impurity (-  -) and a 50 nM 
MDA standard (-  -) for selected reaction times.  At longer reaction times the impurity 
becomes more significant and greatly interferes with low concentrations of MDA. 
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2.3.2 CE Conditions 
Separation conditions attempted using only boric acid were sufficient with water 
as the matrix; however, a substantial destacking effect with Ringer’s solution as the 
matrix was observed due to high salt concentration (Figure 2.4).  One possible remedy is 
to add a surfactant to the BGE at a concentration above its critical micelle concentration 
(CMC).   When potential is applied, the micelles stack at the detector side of the sample 
plug which can help prevent the destacking of the analyte.  Neither sodium 
dodecylsulfate (SDS) nor tetradodecylammonium bromide (TTAB) provided any 
advantage, above or below their respective CMC, over straight boric acid (data not 
shown).  Another approach to this problem is to use a neutral surfactant (i.e. brij 35) to 
increase the viscosity of the BGE in order to slow the adduct based on its hydrophobicity 
as it crosses the sample plug boundary [15, 36].  Brij 35 was used at concentrations 
ranging from below the CMC to well above (0.5, 4.5, and 15 mM) and a large increase in 
sensitivity at 4.5 and 15 mM was observed (Figure 2.4).  A concentration of 4.5 mM was 
chosen because there appeared to be no advantage to using a higher concentration.   
2.3.3 Peak Identification 
To identify the MDA peak an MDA-TBA standard was run first with a UV/Vis 
photodiode array detector connected to the CE system.  The peak at 10.1 minutes was 
easily identified as the adduct based on the UV/Vis spectrum having peak absorbance at 
530 nm, which matched well with literature [1, 10, 37].  The PDA detector was then 
replaced with the fluorescence module and another MDA-TBA standard was run on the 
same capillary producing a similar electropherogram.  The UV data along with varying 
standard concentrations helped further identify the MDA-TBA formation as well as its 
migration time (Figure 2.5).   
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Figure 2.4: A) Electropherograms of 50 nM MDA standards showing destacking effects 
of Ringer’s solution (BGE 200 mM boric acid pH 8.4).  B) Electropherograms of 500 nM 
MDA standards showing the increase in efficiency with added brij 35 (runs were made 
using a Jasco fluorescence detector with a capillary of dimensions 55 (30).   
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Figure 2.5: Electropherograms of (A) 25 µM MDA with PDA detector and (B) 500 nM 
MDA with fluorescence detection (ex 488 nm, em 560 nm).  (C) UV spectrum of the peak 
at 10.1 minutes in plot A. With permission from [35] 
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This method provided a limit of detection of 25 nM (S/N = 3) and a linear range of 
75-9600 nM (5.4-969 ng/ml).  The inter-day coefficient of variance (CV) observed for 
standards ranging from 2500-25 nM were between 7-19% (n=8) ever a 3 month period 
(Figure 2.6).  The high variance for low standards can be attributed to them being at the 
limits of detection for the method. 
Unfortunately a contaminant in the TBA that was unresolvable from the MDA-
TBA adduct.  It was postulated that this contaminate could be a barbituric-thiobarbituric 
adduct formed during the heating.  The barbituric acid contaminate has been previously 
observed and characterized using LC/MS [37]. 
2.3.4 Mass Spectrometric Identification 
The 10 µM MDA standard had an expected [M-H]- peak at m/z 323 representing 
the MDA-TBA adduct (figure 2.7B).  The subsequent collision induced dissociation (CID) 
produced fragments at m/z 264 [M-59]- and 143 [M-180]- which have been previously 
characterized [37].  The blank had a TBA peak m/z 143 which fragmented to m/z 58 [M-
85]-.  Also, there was an unknown peak m/z 301 which fragmented to m/z 258 [M-43]-, 
157 [M-144]-, and 143 [M-158]- ions, and further fragmentation of m/z 157 produced m/z 
98 [M-144-59]-.  The loss of mass 59 (HSCN) from m/z 157 would indicate it has a 
similar structure to TBA and the MDA-TBA adduct.  The fragmentation along with the 
methylene mass difference between m/z 157 and 143 would indicate that the 
contaminant could be residual formaldehyde in the purified TBA.  During the flow 
injection analysis, peaks at m/z 269 and 285 were also identified as barbituric-
thiobarbituric and thiobarbituric-thiobarbituric derivatives.   
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Figure 2.6: Electropherograms of MDA standards and subsequent calibration curve 
(n=8) 
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Figure 2.7: Mass spectra of (A) TBA reagent blank and (B) 10 µM MDA standard after 
derivatization and extraction with butanol.  The m/z 142.8 correlates to TBA, 323 to 
MDA-(TBA), 269 to barbituric-TBA, 285 to TBA-TBA and 301 to the unknown. With 
permission from [35] 
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The interfering peak in the electropherogram could be resulting from the 
methylene-thiobarbituric acid product because it is more structurally similar to the MDA-
TBA product.  TBA was purchased from two venders (Sigma and Cayman) both with 
purity >98% to examine if there would be a difference in the formulation.  Unfortunately, 
no difference in either mass spectra or electropherograms was seen from either vender.   
However, this interfering peak was observed to be consistent from every fresh TBA 
solution made and was less than 25% of the smallest basal MDA detected.  Because 
MDA levels are expected to only increase from the induced oxidative stress, the blank 
was subtracted for quantitation and provided y-intercepts which were closer to zero. 
2.4 MDA in Microdialysis  
2.4.1 Relative Recovery 
To demonstrate this method’s applicability, MDA levels were monitor in a variety 
of rat organs (heart, muscle, and liver).  In vitro studies using a linear microdialysis probe 
of 10 mm showed MDA had a relative recovery of 49 ± 6 % (n=6) at a flow rate of 1 
µL/min which is a reasonable recovery considering MDA’s low molecular weight, and 
with no evidence to suggest MDA will cause a probe failure from sticking to the 
membrane.  MDA was detected in dialysate collected from probes implanted in liver, 
heart and leg muscle (Figure 2.8).  The samples were derivatized as previously stated 
(Section 2.2.2) and compared to standards.  The dialysate concentrations were 
calculated by a calibration curve with linear regression to be: 80 ± 20, 80 ± 8, and 48 ± 9 
nM averaged over 5 basal samples for the liver, muscle and heart respectively.  An 
unreacted dialysate sample was also run and showed no interferences with the MDA 
peak.   
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Figure 2.8: Electropherograms of microdialysis samples collected from liver, heart, and 
muscle and an unreacted (not heated) dialysate sample. With permission from [35] 
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Calibration of a CMA 12 brain probe was also performed.  In vitro experiments 
were performed where the brain probe was submerged in a 500 nM MDA solution 
maintained at 37 °C.  Six MDA standard solutions (0, 100, 250, 500, 750, and 1000 nM) 
were perfused for 50 minutes each, with Ringer’s solution perfused for 30 minutes 
between standards (Figure 2.9).  Samples were collected over 10 minute intervals and 
the last 30 minutes of each standard perfusion period were used to determine the MDA 
relative recovery.  MDA had similar recovery (40%) with the CMA 12 probe as with the 
10 mm linear probe. 
For in vivo calibration, a two point no-net-flux experiment was performed.  A 
basal sample was collected for reference prior to perfusion of 0.4 and 1 µM MDA 
standard solutions, still at 1 µL/min flow rate.  Each standard was perfused for 1 hour to 
allow for equilibration with sample collection over 10 minute intervals.  Ringer’s solution 
was perfused between MDA standards for 30 minutes and basal samples were again 
collected.  The last three samples for each standard were averaged and used to 
calculate MDA relative recovery.  From this two-point calibration, it was determined that 
MDA had a recovery between 40-50% (Figure 2.9).  In another experiment (not shown) 
the recovery was calculated to be 5%, but there was a noticeable decrease in dialysate 
volume indicative of probe failure.  It was not surprising though to have a 10% difference 
within the in vivo calibrations experiments because of the added variable compared to in 
vitro.  It is the purpose of these studies to observe changes relative to basal and control 
levels.  Even with a difference in recovery of 10% or greater from probe to probe, the 
percent change in MDA will still be indicative of changes in vivo.   
 
 
47 
 
 
 
 
 
Figure 2.9: Relative recovery curves for in vitro (A) and in vivo (B) brain microdialysis 
experiments using a CMA 12 probe.  The negative of the slope indicates a RR of about 
40% and the x-intercept is the Cs (concentration in the sample) 
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2.4.2 In Vivo Application 
 The first attempt at inducing oxidative stress was by dosing doxorubicin 
(Adriamycin) through the microdialysis probe into the liver, as done previously in our 
laboratory [38].  However, doxorubicin has fluorescent characteristics matching that of 
the detection scheme used for MDA, and at the concentration being used had large 
peaks interfering with MDA detection.  Solid phase extraction (SPE) using Ziptips 
(Millipore, Billerica, MA) was employed in order to remove doxorubicin from the samples.  
SPE was successful at removal of doxorubicin; however, samples collected during the 
dosing period were too heavily concentrated causing saturation of the Ziptip. The 
remaining doxorubicin during dosing still caused interferences preventing MDA 
quantitation.  Therefore, a model of liver ischemia was used to validate the application of 
this method for in vivo oxidative stress.  Models of liver ischemia/reperfusion are used to 
study injury from liver transplantation [39]; also, conditions of hemorrhaging, severe 
bleeding and infectious diseases can lead the liver to be vulnerable to I/R injury [40].  
Partial ischemia/reperfusion was accomplished here by clamping the left hepatic artery 
for 30 minutes.  Probe performance was monitored by retrodialysis of 5 µM antipyrine in 
Ringer’s solution throughout the experiment as performed previously in our laboratory 
[41].   
 Increases in MDA were inconsistent for ischemia experiments and at first glance 
there appeared to be no correlation in MDA production and liver ischemia (Figure 2.10).  
Of the nine ischemia/reperfusion experiments, two showed no change from basal, five 
had sporadic jumps in MDA at single time points, and two had extended increases in 
MDA over multiple data points.  From these data it can be concluded that either many 
factors are involved in MDA production in the liver or there are inconsistencies with the 
experimental design.   
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Figure 2.10: MDA time plots of three different liver ischemia experiments to illustrate the 
range of MDA produced.  Time 0 represents the start of 30 minute ischemia.  It is 
important to note the change in percent basal of MDA after ischemia and how vastly it 
varies between the three experiments. 
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However, comparing the histology results (cellular necrosis) to their respective 
MDA data for each experiment revealed a damage correlation.  Those experiments 
which had no change in MDA production showed little to no damage to the liver (similar 
to controls) while the liver histology from the experiments with extended MDA production 
showed large amounts of damage and necrosis.  These data would indicate problems 
with reproducibility of the ischemia in the animal model and that the analytical method is 
able to track those differences.  The probe placement also had a factor in the MDA 
recovered.  If the probe was inserted next to an artery or vein then whatever damage 
occurred at the start of reperfusion the probe was able to sample from that immediate 
area.  However, when the probe was located further away from an artery the MDA 
recovered was either delayed because of the diffusion rate through the tissue or a result 
of damage to tissue outside the penumbra.  Figure 2.11 shows three example 
experiments of varying damage in which probe placement could have affected MDA 
recovery results. 
The liver receives blood from two sources, the portal vein and the hepatic artery 
[42].  The portal vein supplies the liver with blood from the gut, spleen, and pancreas as 
part of digestive processes.  The hepatic artery supplies the liver with oxygenated blood 
from the heart.  Blood exits the liver via the hepatic vein into the inferior vena cava 
(heading to the heart).  Partial liver ischemia can be achieved by clamping the portal 
vein, hepatic artery and bile duct of a particular liver lobe [43].  In this work, only the 
hepatic artery was clamped.  It has been stated that portal vein occlusion can lead to 
intestinal pooling of blood producing inflammatory metabolites in the gut [44].  Portal vein 
occlusion causes an increase in animal mortality, but models have been used to produce 
substantial liver injury with only hepatic occlusion [45]. 
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Figure 2.11: Liver histology pictures and their respective MDA time plots. A) Example of 
high damage experiment where the microdialysis probe is located near an artery, the 
time plot shows immediate increase in MDA after ischemia. B) Example of medium 
damage experiment where the microdialysis probe is located further from an artery, the 
time plot shows a delayed increase in MDA (~180 min) with sporadic increase in MDA 
around the ischemia.  C) Example of low damage experiment where although 
microdialysis probe is located near an artery, little MDA or damage was produced.  
White circles highlight probe location, white arrows show artery. 
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In order to prevent a misinterpretation of the data and animal death from 
intestinal byproducts, the hepatic artery was the only blood supply occluded.  However, if 
the hepatic artery is not fully clamped, then the leakage could still provide the liver with 
some oxygenated blood.  A study by Brooks et al. [46] used microdialysis sampling to 
monitor the partial pressures of oxygen and carbon dioxide in patients undergoing liver 
resection surgery.  During the 10 minute clamping of the hepatic vesicular inflow they 
observed a statistical difference in carbon dioxide; however, no significant difference in 
oxygen during the same time period [46].  This lack of statistical difference between 
basal and ischemia was due to a large variation in oxygen during the ischemic period.   
Blood from the portal vein, although not fully oxygenated, could provide enough 
oxygen to prevent the cellular changes leading to oxidative stress.  If for example the 
animal was fasting then little oxygen would be consumed in digestion prior to the blood 
reaching the liver via the portal vein.  An interesting experiment would be to not allow the 
animal food several hours before surgery and compare those experiments to animals 
whom were recently feed.   
2.5 Conclusion 
 A CE-LIF method was developed to detect MDA in microdialysis samples.  This 
method was linear over 3 orders of magnitude.  The method had an LOD adequate to 
detect MDA in microdialysis basal samples from probes implanted in multiple tissue 
sites.  Although a contaminant in the derivatizing reagent was present, the 
electrophoretic interference was consistent within batch to batch reactions and could be 
accounted for in analysis.  To show the applicability, this method was used in an animal 
model of liver ischemia.  Although the resulting MDA data were inconsistent, the 
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variability was with the animal model and not the MDA method.  The MDA results were a 
good indicator of damage and correlated well with the respective histology. 
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Chapter 3: 
Malondialdehyde as a Measure for Lipid Peroxidation in Local 3-MPA Dosing 
Model 
Introduction 
Epilepsy, a neurological disorder affecting nearly 3 million people in the US and 
50 million people worldwide, is defined as having 2 or more unprovoked seizure events 
[1].  It can arise from several mechanisms that include genetic disposition, small 
molecule excitotoxicity, and oxidative stress; however, the initiation of these 
mechanisms remains unclear.  Studies have shown that upwards of 36% of patients with 
epilepsy continue to have uncontrolled seizures even with anti-epileptic therapeutic 
treatment [2].  The most common types of anti-epileptic medications focus on decreasing 
neuronal signal through inhibitory mechanisms such as blocking Na+ channels or 
preventing GABA depletion.  Evidence continues to grow for the role oxidative stress 
plays in the development of epilepsy (for review see Shin EJ [3] and Patel [4]), 
suggesting that oxidative stress and epilepsy have a cyclical nature.  For example, 
oxidative stress caused by a stroke or brain trauma (the second and third leading causes 
of epilepsy) provokes a seizure event which causes more oxidative damage leading to 
further seizures [5].  The opposite would then be a seizure event causing oxidative 
damage followed by repetitive seizure events.  The research goal in our laboratory is to 
monitor biomarkers of oxidative stress during chemically induced seizures. 
3.1 Brain Model of Seizures 
 Animal models for seizures can be produced in several ways, the most common 
being through the addition of a chemical convulsant.  The route through which the 
convulsant is dosed depends on the type of seizure desired, generalized or focal.  A 
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generalized seizure originates at some point and rapidly distributes between networks 
and across hemispheres [6].  A generalized seizure can be produced by dosing a 
convulsant systemically, through i.v. or i.p., and produces tonic-clonic seizures (body 
jerks and twitching).  A focal seizure is limited to one hemisphere and usually within one 
network [6].  In this case, a convulsant is dosed by a microinjection directly into the brain 
or delivered through a microdialysis probe.  An unpleasant smell or small motor 
movement are usually the only symptoms experienced from a focal seizure and because 
of this mild activity usually go undiagnosed. 
3-Mercaptopropinoic acid (3-MPA) is a competitive inhibitor of glutamic acid 
decarboxylase (GAD) (Figure 3.1) preventing neurons from synthesizing gamma-
aminobutyric acid (GABA), a major inhibitory neurotransmitter, from glutamate, the 
brains main excitatory neurotransmitter [7].  Glutamate release is involved in neuronal 
plasticity, memory formation, and excitotoxicity; therefore, its regulation is highly 
important.  When 3-MPA is dosed systemically, there is a differential response to seizure 
induction across brain regions.  Schneider et al. observed increases in muscarinic 
receptor binding in the hippocampus (a structure in the temporal lobe) at the early 
stages of 3-MPA induced seizures but not at post-seizure stages [8].  This suggests that 
the hippocampus has involvement in seizure onset and development but not in seizure 
maintenance as compared to other regions of the brain such as the cerebellum and 
striatum [8].  Animal seizure models in the hippocampus have been used to simulate 
temporal lobe epilepsy.   
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Figure 3.1: Synthesis of GABA from glutamate via glutamic acid decarboxylase (GAD).  
3-MPA is an inhibitor for GAD. 
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3.1.1 Hippocampus 
 The most common human form of epilepsy involves the medial temporal/limbic 
network which includes the hippocampus, amygdala, entorhinal cortex, lateral temporal 
neocortex, medial thalamus and inferior frontal lobes [9].  Evidence points to the 
hippocampus as an origin for temporal lobe epilepsy, in particular, Ammon’s horn 
sclerosis (or hippocampal sclerosis) with damage to the hippocampus pertaining to the 
Cornu Ammonis (CA) region [10].  The hippocampus is comprised of three distinct 
regions; the dentate gyrus, hippocampus proper, and subiculum.  The hippocampus 
proper (CA region) consists of three sub-fields; CA1, CA2, and CA3 all made up of 
pyramidal neurons.  The distinction between these regions comes from the size of the 
neurons (CA3 > CA1) and the direction of signal.  Signaling in the hippocampus runs 
unidirectional, from dentate gyrus to CA3, CA3 to CA1, and CA1 to the stubiculum [11].  
The CA2 field is a fusion between the CA3 and CA1; it has larger neurons like the CA3 
but does not have mossy fiber connections like the CA1; however, the exact functionality 
of the CA2 is unclear.  It has been postulated that seizure activity is a result of the 
hippocampal restructuring of surviving neurons (particularly inhibitory) after the death of 
pyramidal cells [10]. 
3.1.2 Systemic Dosing Model 
 A systemic dosing model of 3-MPA was previously developed in our laboratory 
by Eric Crick [12].  This model produced a steady state of 3-MPA in the brain for 50 
minutes and produced status epilepticus during dosing (Figure 3.2).  Status epilepticus is 
defined as a generalized seizure event where the individual experiences full body 
twitching (clonic-tonic).  In this model, both 3-MPA and the neurotransmitters glutamate 
and GABA were monitored through a microdialysis probe implanted in the hippocampus 
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CA3 region (-5.6 A/P, +4.8 L/M, -7.0 D/V versus bregma).  Glutamate increased about 
200% during and following seizure induction, while GABA decreased during dosing but 
slowly returned to basal levels during recovery period.  This trend follows what is 
expected based on the mechanism of 3-MPA. 
3.1.3 Focal Dosing Model 
 To complement the systemic seizure model a local dosing method for 3-MPA 
was also developed in our laboratory by Andrew Meyer to simulate a focal seizure.  In 
this model, 3-MPA was dosed through the microdialysis probe directly into the 
hippocampus CA1 region (-3.3 A/P, +1.7 L/M, -3.7 D/V versus bregma) [13].  Again, a 
steady-state delivery of 3-MPA to the brain was established for 50 minutes matching the 
conditions from the systemic dosing model (Figure 3.3).  However, because the area of 
dosing was so small, it was difficult to detect seizure (electrical) activity.  In this model, 
there was an increase in glutamate of about 600% during dosing (3 times that of the 
systemic model), but more interestingly GABA also increased during dosing unlike the 
systemic model.   
In order to better understand the mechanisms associated with 3-MPA dosing, the 
extent of lipid peroxidation (as measured by MDA) was determined with local dosing 
between the CA3 and CA1 regions.  Perfusion of glutamate through the microdialysis 
probe elicited a 6-fold increase in MDA production in the cortex [14].  It can be 
anticipated that the perfusion of 3-MPA (which indirectly increases glutamate) should 
also increase MDA production.   
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Figure 3.2: Data from systemic dosing method of 3-MPA: A) Box represents steady state 
of 3-MPA in the brain (line graph) and bar graph shows individual ECoG seizure activity, 
B) Microdialysis data from glutamate (Glu) and GABA as percent basal.  Figures taken 
from Eric Crick, PhD dissertation [12].  
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Figure 3.3: Data from local dosing model of 3-MPA: A) steady state delivery of 3-MPA 
through the microdialysis probe into the brain, B) Microdialysis data from glutamate (Glu) 
and GABA as percent basal.  Figures taken from Andrew Meyer, PhD dissertation [13]. 
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3.2 Methods 
3.2.1 Chemicals 
MDA (malondialdehyde tetrabutylammonium salt), boric acid, 3-mercaptopropionic acid 
(3-MPA) and TBA were purchased from Sigma-Aldrich (St. Louis, MO).  TBA was also 
purchased from Cayman Chemical (Ann Arbor, MI).  Brij 35 was purchased from MP 
Biomedicals (Solon, OH).  Sulfuric acid and salts for Ringer’s solution were purchased 
from Fisher (Fair Lawn, NJ).  Ringer’s solution composition was: 147 mM NaCl, 3 mM 
KCl, 1 mM MgCl2, and 1.2 mM CaCl2.  All solutions were made using nanopure water 
obtained from a Labconco Water Pro Plus purification system (Kansas City, KS). 
3.2.2 CE-Fluorescence Method 
MDA was detected based on the CE-fluorescence method described in Chapter 
2 of this dissertation.  Briefly, 5 µl of microdialysate samples were derivatized with 3.75 
µl of a 2:1 thiobarbituric acid (0.2% w/v) and sulfuric acid (0.2% v/v) mixture in a water 
bath at 90-95 °C for 20 minutes.  The samples were flash frozen in liquid N2 and stored 
at -80 °C until analyzed.  Separation was carried out using a Beckman Coulter P/ACE 
MDQ CE system coupled with a 488 Ag laser module for excitation.  Samples were 
hydrodynamically injected for 5 seconds at 0.5 psi.  The separation was carried out at 10 
kV with a BGE of 200 mM boric acid and 4.5 mM Brij 35 at pH 8.4.  Fluorescence 
detection was achieved with excitation at 488 nm and emission at 560 nm. 
3.2.3 Animal Surgery 
 All animal experiments were performed using male Wistar rats (Charles River) in 
the weight range of 300-500 g.  Rats were housed under a 12 hr day/night cycle and 
given free access to food and water.  All experiments were performed in the morning to 
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account for diurnal fluctuations.  All animal experiments were performed in accordance 
with the local Institutional Animal Care and Use Committee and follow the principles 
stated in the Guide for the Care and Use of Laboratory Animals (National Academy of 
Sciences, 1996).  All chemical solutions used for microdialysis experiments were diluted 
in Ringer’s solution. 
 Rats were pre-anesthetized with isoflurane inhalation to effect and then fully 
anesthetized using a subcutaneous cocktail (ketamine (67.5 mg/kg), xylazine 
(3.4mg/kg), acepromazine (0.67 mg/kg)).  Once under anesthesia, the top of the skull 
was shaved and the rat was placed in a stereotaxic instrument such that the bregma and 
lambda skull points were approximately at the same height.  A lateral incision was made 
exposing the skull, and a CMA 12 microdialysis guide cannula (CMA, N. Chelmsford, 
MA) was slowly implanted into the rat’s hippocampus CA3 region at stereotaxic 
coordinates -5.6 A/P, +4.8 L/M, and -5.0 D/V or CA1 region at -3.3 A/P, +1.7 L/M, and -
1.7 D/V according to The Rat Brain in Stereotaxic Coordinates 2nd Ed [15] (Figure 3.4).  
The guide cannula was lowered to 2 mm above the desired location to account for the 
length of the microdialysis probe.  The guide cannula was secured in place with dental 
cement and the animal was removed from the stereotaxic instrument.  A CMA 12, 2 mm 
length microdialysis probe (CMA, N. Chelmsford, MA), which had been flushed with 
Ringer’s solution for 1 hour, was placed through the guide cannula into the 
hippocampus.  During the experiment animals were maintained under anesthesia with 
intramuscular booster doses of ketamine equal to one fourth the original dose.  Animal 
body temperature was maintained at 37 °C using an electronically controlled heating 
pad. 
 
 
66 
 
 
 
 
 
Figure 3.4: Diagram of the two brain regions of the hippocampus, the left is the CA1 and 
right CA3.  Dark rectangle represents the guide cannula and the open rectangle 
represents the microdialysis probe.  Image taken with permission from [15]. 
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3.3 MDA from Local Dosing of 3-MPA  
3.3.1 MDA Reaction Modification 
 For the reaction the same MDA:TBA:acid ratio of 8:2:1 as described in Chapter 2 
was used, but because samples were split between multiple methods (including a 
nitrite/nitrate method) only 5 µL of sample was allocated for this method.  To keep the 
same ratio as previous 1.875 µL of the TBA/acid mixture would have to be added to the 
5 µL of sample making a total volume of 6.875 µL.  However, under these reaction 
conditions, there was a large increase in the contaminant in the blank.  This was 
believed to be a result of evaporation from heating such a small volume.  To increase 
the volume without altering the reaction ratio, the TBA and sulfuric acid were mixed 
(40:20) and then diluted in half with water.  Then, 3.75 µL of that mixture was added to 
the 5 µL of MDA standard or sample in a 200 µL microcentrifuge tube.  This did alleviate 
the large peak from the impurity in the blank, but at the expense of loss in sensitivity 
from dilution.  All other parameters as described in Chapter 2 were not changed. 
3.3.2 Delivery of 3-MPA through Microdialysis Probe 
 Ringer’s solution was perfused for 1 hour after probe implantation prior to the 
start of basal collection.  All animal experiments used a perfusion flow rate of 1 µL/min 
and samples were collected over 10 minute intervals.  After the collection of 1 hour of 
basal (6 samples), the perfusate was switched to a 3-MPA solution (10, 1, or 0.1 mM in 
Ringer’s solution) and perfused for 50 minutes.  Following the 3-MPA perfusion period 
the inlet was reconnected to Ringer’s solution and allowed to perfuse for 4 hours.  For 
control experiments the inlet tubing was removed and reattached from the syringe to 
simulate switching between Ringer’s solution and 3-MPA solutions.  All samples were 
stored at -80°C until analyzed.  At the completion of the experiment the animals were 
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euthanized via isoflurane inhalation overdose.  Rat brains were harvested and stored in 
neutral buffered formalin solution for histological evaluation. 
3.3.3 Varying 3-MPA Concentrations between Regions 
 3-MPA was dosed at 3 different concentrations (10, 1 and 0.1 mM) in order to 
correlate the lipid peroxidation to convulsant dosed.  We hypothesized that with every 10 
fold increase in 3-MPA there would be a 10 fold increase in MDA.  A correlation between 
glutamate and GABA with the concentration of 3-MPA dosed was anticipated.  Previous 
work in our laboratory developing the local dosing model used only 10 mM 3-MPA in the 
CA1 region [13].  Therefore, 3-MPA was dosed in both the CA1 and CA3 regions at 
varying concentrations in order to better understand the local dosing model and relate 
the data here to previous experiments. 
3.3.4 Statistical Difference in MDA between Dosing Regimens 
 In the CA3 region, the 10 mM 3-MPA perfusion showed significant (p<0.001) 
increases compared to control MDA 20 minutes after the start of perfusion and remained 
high for 3 hours after dosing had stopped (Figure 3.5).  MDA steadily increased 
throughout the 3-MPA perfusion reaching a maximum of about 7 µM and decreased 
following the cessation of 3-MPA perfusion; however, never returning to control levels.  
The 1 and 0.1 mM 3-MPA perfusions showed similar increases in MDA both reaching 
maxima of 1500 nM; however, these data did not show significant differences when 
compared to control using the Tukey multiple comparison test [16].  The 10 mM 3-MPA 
dose was statistically different from both the 1 and 0.1 mM during the perfusion through 
30 minutes post 3-MPA perfusion.   
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Figure 3.5: Time plots of MDA concentration recovered in microdialysate samples from 
hippocampus CA3 region as a function of concentration.  3-MPA perfusions experiments 
of 10 mM (-   -) (n=5), 1 mM (-   -) (n=6), 0.1 mM (-   -) (n=5), and control (-   -) (n=5).  
Time zero represents the start of 3-MPA perfusion for 50 minutes (indicated by bar).  (* 
p<0.001 for 10 mM perfusion by one-way ANOVA F(3,12) = 0.05 with Tukey multiple 
comparison)   
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Figure 3.6: Time plots of MDA concentration recovered in microdialysate samples from 
hippocampus CA1 region as a function of concentration.  Time zero represents the start 
of 3-MPA perfusion for 50 minutes (indicated by bar).  3-MPA perfusions experiments of 
10mM (-   -) (n=5), and 1 mM (-   -) (n=3).  (* p<0.001 for 10 mM perfusion t-test)  
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In the CA1 region, the 10 mM 3-MPA perfusion had significant increases during 
and after perfusion as well as the 1 mM dose (Figure 3.6).  MDA did not return to basal 
in either dosing regimen.  Because there were no differences in the 1 mM doses 
between the two regions as well as between the 1 mM and 0.1 mM within the CA3 
region, 3-MPA was not dosed at 0.1 mM to the CA1 region.  
3.4 Glu/GABA from Local Dosing of 3-MPA  
3.4.1 LC-Fluorescence Method for Glutamate and GABA 
 Microdialysis samples were analyzed for glutamate and GABA using NDA/CN 
derivatization reaction [12, 17, 18].  A 1 µL aliquot of sample was added to 2 µL of a 5 
mM NaCN and 100 mM Borate (pH 9.2) mixture.  To that, 1 µL of 1 mM NDA (in 50% 
MeOH/water) was added, vortexed and allowed to react in the dark for 30 minutes.  A 3 
µL injection of sample was separated using a Synergy Hydro-RP 80A 150 x 2.00 mm 4 
µm C18 column (Phenomenex) with a two solvent LC gradient system (Shimadzu LC-
20AD pumps) consisting of 50 mM ammonium acetate, 5% THF (Solvent A) and MeOH 
(Solvent B) at a flow rate of 0.350 mL/min.  Initial conditions were 45% Solvent B with a 
linear increase to 60% from 0-7.5 minutes, then an increase to 80% from 7.5-8.5 
minutes.  Solvent B was held at 80% for 0.5 minutes then returned to 45% for a 2 minute 
re-equilibration.  Derivatives were detected using fluorescence detection (Jasco FP 
2020) at 490 nm with excitation at 442 nm.  Example chromatograms from hippocampus 
microdialysis sample can be seen in Figure 3.7. 
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Figure 3.7: LC-fluorescent example chromatograms from NDA/CN derivatization method 
for amino acids glutamate and GABA (2 µM standards, basal, during 3-MPA dosing, and 
post 3-MPA dosing dialysate).   
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3.4.2 Increases in both Glutamate and GABA 
 Levels of glutamate and GABA were monitored for all three dosing methods in 
the CA3 region, but only the 10 mM dose showed any statistical changes when 
compared to controls.  Both neurotransmitters increase upon dosing of 10 mM 3-MPA to 
about 500% basal and remained above basal levels for over 3 hours post dose.  
Although both neurotransmitters increased from 3-MPA dosing, GABA showed the more 
statistically significant increase (p<0.01) than glutamate (p<0.05) during the same time 
period (Figure 3.8).  Microdialysis studies of temporal lobe epilepsy in humans showed 
increases in glutamate (3 min prior to seizure) and GABA (at the onset of seizure); 
however, GABA concentrations quickly returned to basal (<10 min post seizure) while 
glutamate remained elevated (>20 min) [19].  These data are from patients with complex 
partial epilepsy where the seizures were spontaneous.  The delayed increase in GABA 
would indicate a protective measure against seizures as a result of the elevated 
glutamate, but it is intriguing that GABA levels decreased after a seizure while glutamate 
remained high.  The results from the research here show that during and post 3-MPA 
perfusion, GABA remains elevated and follows glutamate very closely.  Unfortunately, 
temporal resolution was sacrificed to allow for enough sample for multiple methods, so it 
could not be determined if there was a delay in GABA compared to glutamate.   
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Figure 3.8: Time plots of GABA (A) and glutamate (B) recovered from microdialysate 
samples from hippocampus CA3 region as a function of percent basal.  Time zero 
represents start of 10mM 3-MPA perfusion for 50 minutes (indicated by bar).  (A) Plot of 
GABA (-  -) (n=5) and control (-  -) (n=3).  (B) Plot of glutamate (-   -) (n=5) and control (-   
-) (n=3).  (* p<0.01 and ** p<0.05 based on t-test) 
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 The increase in extracellular levels of GABA from local dosing of 10 mM 3-MPA 
was unexpected considering the mechanism of 3-MPA induced seizures.  Previous 
reports have observed a decrease in GABA with i.v. or i.p. dosing of 3-MPA [20, 21].  
This increase could be a result of 3-MPA acting as a competitive inhibitor of GABA 
transaminase [7] preventing the recycling of GABA through glial cells.  This mechanism 
is not usually seen in animal models because the concentration of 3-MPA required for 
GABA transaminase inhibition would result in animal death.  The i.v. or i.p. dosing 
produces global distribution of 3-MPA to the entire brain via the blood, while the local 
dosing through the microdialysis probe is limited by diffusion through the extracellular 
space.  Studies indicate that the local dosing of antiepileptic drugs not only decreased 
seizure intensity but also limited the severe adverse side effects associated with 
systemic dosing, providing the possibility of better treatments for epilepsy [22-24].  It is 
reasonable then, that dosing 3-MPA through the probe could provide a high enough 
concentration around the probe for inhibition of GABA transaminase without resulting in 
animal death.  However, with GAD inhibition by 3-MPA it has been reported that GABA 
was not completely depleted in synaptic terminals of hippocampal slices after prolonged 
3-MPA dosing, implying a high reuptake of GABA into the neuron [25].  This would 
indicate that GABA transport to the glial cell is not the predominant route in the brain 
making it unlikely that the increase in GABA observed here is a result of GABA 
transaminase inhibition.   
3.4.3 GAD Isoforms 
 It has also been suggested that 3-MPA is selective for the vesicular GAD isoform 
(GAD65) and does not have an effect on the cytosolic isoform of GAD (GAD67) [26, 27].  
If this were the case, the synthesis of GABA responsible for inhibition (i.e. synaptic 
GABA) would still be hindered, allowing excitotoxicity through glutamate buildup, while 
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intracellular GABA pools would remain unchanged [27].  The observed increase in 
GABA could be a result of these cytosolic pools being released upon cellular apoptosis.  
The microdialysis probe was placed in the CA3 region of the hippocampus, which 
receives mossy fiber input from the dentate gyrus, comprised of a large amount of 
GABAergic neurons known as basket cells [11].  The increase in extracellular GABA 
observed could be a result of the apoptosis of these GABAergic neurons as a result of 
excitotoxicity. 
 Mathews et al. also observed increases in GABA when dosing glutamate, and 
suggested that extracellular glutamate is transported directly into the inhibitory neuron 
and converted to GABA for subsequent release [25].  The amount of GABA present 
could be directly related to the number of inhibitory neurons located around the probe.  If 
the 3-MPA is only inhibiting the GAD65, then uptake of the excess glutamate could be 
converted to GABA through GAD67 and subsequently released.  This could explain the 
larger GABA increases in the CA3 region (rich with inhibitory neurons) compared to the 
CA1 (lacking inhibitory neurons) while the changes in glutamate were equal in both 
regions.  It should also be noted that the basal concentrations of GABA in the CA3 
region were greater than that of the CA1 region.  This would indicate that the CA3 region 
has a greater threshold for seizure mitigation than the CA1.   
3.5 Neuromechanisms 
3.5.1 MDA in the Hippocampus 
 The increases in MDA observed from the CA3 region did not show a linear dose 
dependence with 3-MPA, which is interesting considering the magnitude between each 
3-MPA dose.   Dosing of 3-MPA systemically has shown a decrease in NMDA receptor 
ligand binding in the hippocampus relative to the rest of the brain [28].  Also, with 
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repetitive doses of 3-MPA NMDA receptor subunits are down regulated [29].  These 
decreases in NMDA activity would indicate a protective effect in the hippocampus 
against 3-MPA induced seizures.   This could indicate a minimum threshold of glutamate 
required for excitotoxicity.  While there were no changes in glutamate or GABA for the 1 
and 0.1 mM 3-MPA dosing, the 10 mM dose resulted in about a 500% increase in both 
neurotransmitters.  Because there is no linear correlation between Glutamate/GABA and 
3-MPA it is not surprising that there is not a linear correlation between MDA and 3-MPA. 
There was a differential increase (p<0.001) in MDA between the CA3 and CA1 
regions (Figure 3.9).  Dosing 10 mM 3-MPA produced over twice as much MDA in the 
CA3 region than in the CA1 region based on the area under the curve (AUC) for their 
respective MDA time plots (Table 3.1).  The CA3 region has been shown to have a 
higher density of cyclooygenase-2 than the CA1 [30, 31] indicating a greater potential for 
lipid breakdown through the arachidonic acid cascade, ultimately producing more MDA.  
Interestingly, the 1 mM dosing produced similar maximum responses in both regions 
(Figure 3.10).  As stated above, this could be due to similar protective effects throughout 
the hippocampus.  However, the AUC for the 1 mM dose in the CA3 region is again 
about twice as much as that from the CA1 region.  Taken together the CA3 region may 
be more susceptible to lipid peroxidation and therefore at greater risk to oxidative 
damage.   
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Figure 3.9: Time course of MDA recovered from 10 mM 3-MPA perfusion in the two 
regions of the hippocampus, CA3 (-   -) (n=5) and CA1 (-   -) (n=5).  Time zero 
represents the start of the 10 mM 3-MPA perfusion for 50 minutes (indicated by bar).  (* 
p<0.001 and ** p<0.02 based on t-test) 
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Figure 3.10: Time course of MDA recovered from 1 mM 3-MPA perfusion in the two 
regions of the hippocampus, CA3 (-   -) (n=6) and CA1 (-   -) (n=4).  Time zero 
represents the start of the 10 mM 3-MPA perfusion for 50 minutes (indicated by bar).  
(No statistical difference was calculated between regions for 1 mM dose) 
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Region  CA3   CA1 
3-MPA Dose 10 mM 1 mM  10 mM 1 mM 
Maximum MDA 7 ± 1 µM 1.4 ± 0.5 µM  4 ± 1 µM 1.3 ± 0.3 µM 
AUC 707,000 290,000  300,000 150,000 
 
Table 3.1: Data from microdialysis plots for both hippocampus regions CA1 and CA3.   
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3.5.2 GABAergic Neuronal Projections 
 When L-trans-pyrrolidine-2,4-dicarboxylic acid (PDC), a Glu/Asp uptake blocker, 
was dosed through a microdialysis probe in the cortex there was an observed increase 
in MDA production resulting from elevated extracellular glutamate [14].  Interestingly, 
when PDC was administered to the thalamus by microinjection there was an observed 
increase in Glu, Asp, and GABA through microdialysis sampling [32].  This work was 
performed on genetic absence epilepsy rats and suggests that increases in GABA could 
result in absence of seizures by lowering membrane potentials.  The same group also 
observed increases in both glutamate and dopamine when dosing PDC through the 
microdialysis probe suggesting that dopamine release can be regulated by glutamate 
efflux possibly influencing further neuronal excitation [33].  The local dosing of 3-MPA 
may result in a cyclical effect where increased glutamate produces MDA, resulting in 
neuronal degradation and release of GABA that drops membrane potentials furthering 
excitotoxicity from glutamate. 
Work by Meurs et al. was performed where three different chemical convulsants 
were dosed through the microdialysis probe into the hippocampus: a muscarinic agonist, 
GABAA receptor antagonist, and glutamate agonist [34].  Glutamate and GABA 
increased during seizures in all three groups.  Their findings along with the results here 
suggest that GABA and glutamate levels are responsive to neuronal stimulation rather 
than the pharmacology of the chemical convulsant [34].   
3.5.3 Enzymatic Pathways Leading to MDA 
  Studies shown a high density of cyclooxygenase (COX)-2 around the CA3 
region of the hippocampus compared to the CA1 [30, 31, 35].  COX-2, the inducible 
isoform of COX, is primarily responsible for inflammation and synthesizes prostaglandins 
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from arachidonic acid in the brain.  COX-2 is upregulated during synaptic activity [31] 
and it has been correlated with oxidative stress [36, 37].  Inhibition of COX-1 and -2 have 
led to a retarding of seizure intensity in an animal kindling model [35].  When 3-MPA is 
dosed the increase in glutamate could cause an upregulation of COX-2 leading to 
excess lipid peroxidation.  The large increase in MDA associated with the 10 mM 3-MPA 
dose could be related, in part, to the increased activity of COX-2 in the CA3 region.   
 Recently, Abdel-Zaher et al. dosed ciprofloxacin to induce seizures in mice and 
examined the resulting oxidative stress [38].  They observed increases in glutamate, 
MDA and nitric oxide (via nitrite) upon dosing of ciprofloxacin.  Interestingly, when 
aminoguanidine was administered prior to ciprofloxacin, MDA and nitric oxide production 
were mitigated while glutamate remained elevated.  Because aminoguanidine is a nitric 
oxide synthase inhibitor nitric oxide levels should drop back to control; however, the 
excitotoxicity from elevated glutamate could still lead to increased MDA versus control.   
Abdel-Zaher et al. also observed enhanced production of nitric oxide and MDA 
with the pretreatment of L-arginine while glutamate did not change from ciprofloxacin 
alone [38].  L-arginine is the primary substrate for nitric oxide synthase.  These findings 
would indicate that MDA production is more closely related to the nitric oxide pathway 
rather than glutamate excitotoxicity.  Of course this work was done using a general 
seizure model in mice with whole brain homogenates indicating that individual brain 
sections, such as the hippocampus, could have other mechanisms leading to MDA 
synthesis.  Nevertheless, these findings indicate MDA production in the brain is 
correlated to some extent with nitric oxide synthase.   
3.6 Conclusion 
83 
 
Although the exact cellular mechanisms leading to MDA production in the brain 
still remain unclear, evidence indicates a differential response to 3-MPA within the 
hippocampus.  The CA3 region produced over twice as much MDA as compared to the 
CA1 region with local dosing of 3-MPA.  Also, a differential release of GABA between 
the two regions was observed, with the CA3 releasing more than the CA1.  Microdialysis 
sampling allowed for the spatial and temporal resolution to both sample and dose within 
these two regions.   
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Chapter 4 
LC/MS Method Development for Eicosanoids 
Introduction 
Enzymes involved in the inflammatory response facilitate the lipid oxidation 
process.  Cyclooxygenase (COX), in particular, is involved in the metabolism of 
arachidonic acid (AA) synthesizing a class of eicosanoids known as prostaglandins.  
COX is a heme containing enzyme with two catalytic sites; the first adding two oxygen 
molecules to AA to form the hydroxyendoperoxide prostaglandin G2, and the second site 
which reduces PGG2 to prostaglandin H2, a precursor for several prostaglandins (Figure 
4.1) [1].  Studies of pro-inflammation have shown increases in 6-keto-prostaglandin F1α 
[2, 3], prostaglandin E2, D2, and 8-iso prostaglandin F2α [4], and thromboxane B2 [2].  
Research has shown that PGE plays a role in neurotransmission and plasticity via PGE 
receptors (EP) in the hippocampus [5, 6].  These EP receptors activate adenyl cyclase 
(increasing cAMP) or release intracellular Ca2+ [6] leading to glutamate release and 
further synaptic activity.  In this instance PGE synthesis and EP receptor activity acts as 
a positive feedback loop for COX-2 expression [5], which can be greatly exacerbated 
during a seizure event.  Also, the free radical isoprostane 8-isoPGF2α has become a 
marker for the non-enzymatic oxidation of arachidonic acid [7-9].  Figure 4.1 shows the 
metabolites of interest in the arachidonic acid cascade.  The main mechanism of lipid 
peroxidation proposed here involves COX, therefore the lipooxygenase product 
leukotriene B4 (LTB) was used as a general marker of stress. 
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Figure 4.1: Eicosanoids of interest involved in the arachidonic acid cascade.  Adapted 
from (Sang, N 2006).   
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Methods used to evaluate eicosanoids typically involve immunoassays [3, 4, 7, 
10], fluorescent labeling [11] or LC-MS [12, 13].  Immunoassays, however, can only 
facilitate the detection of one analyte at a time, and for the purpose of this study too 
much dialysate would be required to monitor every compound of interest.  Previous 
microdialysis methods used for prostaglandins have involved high flow rates (~5 µL/min) 
and long collection intervals (>20 minutes) [8, 13].   
Eicosanoids are difficult to detect using spectrometric methods because they do 
not have the structural characteristics to allow for UV/Vis absorbance or fluorescence 
detection.  Derivatizing agents such as 1-pyrenyldiazomethane (PDAM) [11] and 9-
anthryldiazomethane (ADAM) were attempted but because of the bulkiness of the 
fluorophore, a separation of prostaglandin isomers was not attainable.  The use of a 
mass spectrometer, which does not require derivatization, is a more appropriate 
technique from this application.  Here, an LC separation coupled with mass spectrometry 
detection was developed for the detection of 7 eicosanoids; 6-ketoprostaglandin F1α (6-
keto), thromboxane B2 (TXB), 8-isoprostaglandin F2α (8-iso), leukotriene B4 (LTB) and 
prostaglandins F2, E2, and D2 (PGF, PGE, and PGD respectively).   
4.1 Mass Spectrometry 
 Mass spectrometry (MS) is a secondary separation technique for gaseous phase 
ions.  Analytes are ionized by an ionization source then separated based on their mass 
to charge ratio (m/z) in a mass analyzer and detected.  Ionization sources are 
appropriate for analytes based on chemical characteristics (e.g. volatility, functional 
groups, etc.).  Mass analyzers use electrostatic forces to separate ions with an exact m/z 
so they can be individually detected.  The resolution at which mass analyzers detect ions 
is based on the following equation: 
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There are two ways to calculate resolution [14].  The first involves the resolution 
between two peaks where the valley between the two ions is 10% of either one.  In this 
case, ΔM is the difference between the two masses and M is the mass of the larger peak 
[15].  The second is calculated for a single peak by its full width at half maximum height 
(FWHM).  Here M is the mass number of the peak and ΔM is the width of the peak [14].   
4.1.1 Ionization  
To incorporate MS with LC separations, ionization techniques such as 
electrospray ionization (ESI) were developed which facilitate the volatilization of ions 
from the aqueous solutions [16, 17].  ESI is a soft ionization technique where solvent 
continually flows through a nebulizing tip with a positive voltage applied across it adding 
excess protons to the solution droplets (if a negative voltage is applied, the solution 
becomes void of protons) [18].  The excess protons will protonate molecules with basic 
functional groups, while a negative voltage will deprotonate acidic functional groups.  
The solvent droplets are evaporated using gas (e.g. nitrogen) before entering the mass 
analyzer.  There are two schools of thought as to exactly how ions enter the gas phase; 
the charge residue model (CRM) and the ion desorption model (IDM) [14].  In the CRM 
model, as the droplets shrink the charge density on the surface reaches the Rayleigh 
instability limit and the Coulombic repulsive forces exceed the surface tension causing 
an explosion creating gas phase ions [18].  According to the IDM, as droplets shrink the 
surface charge becomes great enough to overcome the cohesive forces within the 
droplet causing an ion to be ejected [19].  Figure 4.2 diagrams the processes involved in 
ESI. 
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Figure 4.2: Electrospray ionization in positive ion mode with Taylor Cone formation at the 
needle tip.  Examples of both charge residue model (CRM) and ion desorption model 
(IDM) of gaseous ions is shown. Taken with permission from [20] (pg 2) 
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4.1.2 Mass Analyzers 
 Mass analyzers use electric and magnetic fields to manipulate gaseous ions from 
the inlet to the detector.  Analyzers are under high vacuum (about 10-5 torr) in order to 
prevent inadvertent collisions from other species.  Analyzers can scan through a range 
of m/z (allowing one m/z at a time to be detected) producing a mass spectrum or can be 
selective to allow only one ion to be detected.  Common mass analyzers include time-of-
flight (TOF), quadrapole, ion trap, and ion cyclotron resonance.   
 A 3D ion trap is in a donut shape and consists of three electrodes; one ring and 
two endcaps while a linear ion trap (used here) is cylindrical “box” made up of four 
quadrapoles [21].  For analysis the ion trap is first filled with ions, and then it uses 
isolation waveforms to eject the ions sequentially for MS1 analysis (Figure 4.3).  An ion 
trap can also use the isolation waveforms to eject all ions except the m/z of interest.  The 
trap can then induce fragmentation of the isolated ion (usually with an inert gas), 
followed by an MS2 analysis ejecting all product ions for detection.  Unlike other mass 
analyzers, the ion trap has the ability to perform repeated MS experiments (isolate, 
fragment, isolate, fragment, etc.) so long as there are ions remaining in the trap.  MS 
experiments where specific parent/product ion pairs (transitions) are detected can be 
used to greatly increase selectivity and sensitivity for an analyte [22].  These types of 
experiments are known as single reaction monitoring (SRM), or multiple reaction 
monitoring (MRM) in the case of several product ions, and will be used here for the 
detection of arachidonic acid metabolites.   
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Figure 4.3: Illustration of the linear ion trap with dual detector systems used in this 
method (Thermo Scientific website product support bulletin [23])  
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4.2 Methods 
4.2.1 Chemicals 
All of the PGs were purchased from Cayman Chemicals (Ann Arbor, MI) are 
easily dissolved in organic solvent (methanol, ethanol, DMSO, etc.) and can be diluted 
with water at lower concentrations.  Stock solutions of either 100 or 50 µM were made 
for each analyte in methanol.   Any dilutions made were no greater than 1:20.  Large 
dilution factors led to the more hydrophobic species (i.e. LTB) falling out of solution.  
HPLC grade acetonitrile (ACN), methanol, and the salts for Ringer’s solution were 
purchased from Fisher (Fair Lawn, NJ).  Ringer’s solution composition was: 147 mM 
NaCl, 3 mM KCl, 1 mM MgCl2, and 1.2 mM CaCl2.  Acetic acid (>99.99%) and 3-
mercaptopropionic acid (3-MPA) was purchased from Sigma-Aldrich (St. Louis, MO).  All 
solutions were made using nanopure water obtained from a Millipore Advantage A10 
purification system (Billerica, MA). 
4.2.2 LC Conditions 
A two solvent gradient system consisting of Shimadzu LC20 ADxr pumps and 
CBM-20A system controller were used for prostaglandin separation.  Solvent A was of 
0.05% acetic acid and solvent B 0.05% acetic acid in ACN.  The initial conditions were 
30% solvent B with a flow rate of 0.200 mL/min with the column oven (Shimadzu CTO-
10A) set at 30 °C.  A two-step linear gradient was employed: 0 to 6.5 minutes solvent B 
increased from 30 to 54%, then from 6.5 to 9 minutes solvent B increased from 54 to 
80%.  Solvent B was held at 80% for 30 seconds and for re-equilibration dropped back 
down to 30% from 9.5 to 9.8 minutes and held from 9.8 to 12 minutes.  A Phenomenex 
Kinetex XB-C18 column with dimensions of 100 x 2.1 mm ID, and 1.7 µm particle size 
was used.  Prior to injections, a 10 µL syringe was rinsed with 80% ACN followed by 
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25% ACN (rinsing with only 25% ACN lead to sample carry over).  After rinsing, 5 µL of 
sample/standard were injected into a Rheodyne 7725i manual injector fitted with a 10 µL 
sample loop.  All lines and fittings pre-column were stainless steel and post-column were 
0.25 x 0.005 inch (OD x ID) PEEK tubing.   
4.2.3 MS Conditions 
MS analysis was performed on a Thermo LTQ-XL linear iontrap mass 
spectrometer.  Each analyte was individually tuned using high flow rate flow-injection 
analysis with Thermo LTQ Tune software.  A 500 µL Hamilton syringe was filled with an 
individual standard (~20 µM) and placed into a syringe pump set at 5 µL/min.  The 
syringe was split into the LC line using a T-junction for a total flow of 0.200 mL/min.  The 
mobile phase composition was equivalent to that during the expected elution time for the 
given analyte.  For each MS segment, the Sheath Gas was set at 25, Auxiliary Gas set 
at 2, Ion Spray Voltage set at -3.5 kV and Capillary Temperature set at 275 °C. 
LC-MS method development and analysis was performed using Xcalibur 
software.  During runs, the diverter valve was set to the waste position for the first and 
last 2 minutes.  Seven MS segments were used for the method.  Segments 1 and 7 were 
the waste segments (2 min each) and set for MS1 with a scan range of 295-390 m/z.  
Segment 2 (1.61 min) had 2 scan events: 1) SRM 369 to 315 m/z for 6-keto and 2) SIM 
105 m/z for 3-MPA.  Segment 3 (0.75 min) had 2 scan events: 1) MRM 353 to 273, 299, 
and 309 m/z for 8-isoPGF and 2) MRM 369 to 169 and 195 m/z for TXB.  Segment 4 
(0.45 min) had 1 scan, MRM 353 to 273, 299, and 309 m/z for PGF.  Segment 5 (1.51 
min) had 1 scan: MRM 351 to 233, 315, and 333 m/z for PGE and PGD.  Segment 6 
(3.66 min) had 1 scan: MRM 335 to 195 and 317 m/z for LTB.  Table 4.1 is a summary 
of the MS settings for each segment and subsequent transitions. 
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Segment Time (min) Parent ion 
(m/z) 
Isolation 
width (m/z) 
CID Product ions 
(m/z) 
2 1.61 369 4.0 40 315 
- - 105 - - - 
3 0.75 353 3.0 30 273, 299, 309 
- - 369 5.0 40 169,195 
4 0.45 353 3.0 30 273, 299, 309 
5 1.51 351 4.0 40 233, 315, 333 
6 3.66 335 3.5 30 195, 317 
 
Table 4.1: MS/MS settings for scans from individual segments 
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4.2.4 Microdialysis Application 
4.2.4.1 In Vitro  
 In vitro experiments were performed to evaluate these eicosanoids for 
microdialysis sampling for the eventual application to the 3-MPA seizure model from 
Chapter 3.  A CMA 12 2 mm probe with MW cutoff of 20 kDa with a perfusate flow rate 
of 1 µl/min was used.   
The in vitro experiment involved moving the microdialysis probe between 
solutions of Ringer’s and eicosanoid standards (sample switching); this is a strict 
recovery experiment.  The “sample” vials were heated to ~37 °C and lightly stirred.  The 
microdialysis probe was initially placed in the Ringer’s solution sample for 1 hour then 
moved to a solution of 50 nM eicosanoids for 1 hour followed by a solution of 100 nM 
and then back to the Ringer’s solution.  The process was repeated, however, in reverse 
order (100 nM, 50 nM, and then Ringer’s).   
4.3.4.2 In Vivo Animal Model 
 The same animal procedure as described in Chapter 3 was used here.  Briefly, 
rats were anesthetized using a subcutaneous cocktail (ketamine (67.5 mg/kg), xylazine 
(3.4mg/kg), acepromazine (0.67 mg/kg)).  A lateral incision was made exposing the 
skull, and a CMA 12 microdialysis guide cannula (CMA, N. Chelmsford, MA) was slowly 
implanted into the rat’s hippocampus CA3 region at stereotaxic coordinates -5.6 A/P, 
+4.8 L/M, and -5.0 D/V according to The Rat Brain in Stereotaxic Coordinates 2nd Ed 
(Paxinos and Watson).  A CMA 12 2 mm microdialysis probe (CMA, N. Chelmsford, 
MA), which had been flushed with Ringer’s solution for 1 hour, was placed through the 
guide cannula into the hippocampus.   
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All animal experiments were performed using male Wistar rats (Charles River) 
that had been housed under a 12 hour day/night cycle and given free access to food and 
water.  All experiments were performed in the morning to account for diurnal fluctuations.  
All animal experiments were performed in accordance with the local Institutional Animal 
Care and Use Committee and follows the principles stated in the Guide for the Care and 
Use of Laboratory Animals (National Academy of Sciences, 1996).  All chemical 
solutions used for microdialysis experiments were diluted in Ringer’s solution. 
4.3 Separation 
4.3.1 Column Selection 
 Reverse phase separation using a C18 stationary phase is the most appropriate 
conditions for the separation of eicosanoids.  The make-up of the bonded phase had a 
dramatic effect on the efficiency of 6-keto.  The type of silica used and the end-capping 
would dictate the broadness of the 6-keto peak at a much larger degree than the other 
compounds.  This was interesting because 6-keto was the first peak to elute, and usually 
in LC broadening is more pronounced with later eluting compounds.  The Luna C18 (2) 
column from Phenomenex gave the best peak shape and efficiency, most likely because 
it has the smoothest silica surface compared to other columns.  However, with the Luna 
column, run times were over 30 minutes and there was large amount a noise, possibly 
from column bleed.  A new technology, the Kinetex column from Phenomenex, using 
solid core particles (limiting multiple paths) was implementing to help decrease the run 
times.  The Kinetex column not only decreased the run time to less than 10 minutes, but 
it also had less noise and maintained the peak integrity of 6-keto.   
4.3.2 Mobile Phase 
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 Reports using LC-MS to detect eicosanoids have used negative ion mode with 
either formic or acetic acid [12, 13].  The production of negative ions under acidic 
conditions is not ideal; therefore, both acidic and basic mobile phases were evaluated 
along with varying organic solvents.  Aqueous solutions (Solvent A) attempted consisted 
of 0.05 % acetic acid, 0.1 % formic acid, or 10 mM ammonium acetate, with organic 
solvent (Solvent B) of either acetonitrile or methanol.  The use of formic acid leads to 
diminished signal with negative ion mode [13] and therefore was not used.  The two 
optimal mobile phases for acidic and basic conditions were 0.05% acetic acid/ACN and 
10 mM ammomium acetate/MeOH respectively.  Using the acetic acid mobile phase 
TXB and 8-IsoPGF were unable to be resolved chromatographically.  While using the 
ammonium acetate mobile phase all analytes were resolved chromatographically; 
however, the signal from 6-KetoPGF was diminished.  Because TXB and 8-iso have 
different m/z’s (369 and 353 respectively) the acetic acid/ACN mobile phase was chosen 
because of the better detection of 6-keto. 
4.3.3 Gradient Profile 
 Since the range of hydrophobicity between the eicosanoids would lead to 
excessively long retention times using an isocratic system, a gradient profile was 
employed.  A single linear gradient (30-55% for 0-15 min) produced sufficient resolution 
for all analytes.  To reduce run times but not lose resolution, a 2 point linear gradient 
was used, which only decreased the retention time of LTB making the entire analysis  
less than 15 min (including re-equilibration).   
4.4 Tandem MS 
4.4.1 Full-Scan MS1 
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 For initial identification and method development the mass spectrometer was set 
at scan mode covering the range of the PGs and possible adducts (m/z 300-400).  This 
mode was also used when adjusting the gradient or varying mobile phases to identify 
peaks.   
4.4.2 MRM Development 
 Once peaks were identified from the MS1 analysis (including the co-eluting TXB 
and 8-IsoPGF) the MS was set for collision induced dissociation (CID) on isolated parent 
ions.  Arbitrary CID units of 22 were initially used for all parent ions as this was adequate 
to product fragmentation with flow injection analysis.  The product ions were scanned 
and individual ion chromatograms that had the best S/N were selected for MRM.  The 
selected ion transitions can be seen in Table 4.1.  Figures 4.4 – 4.10 are CID product 
spectra for each eicosanoid.   
4.4.3 S/N Optimization 
Several parameters of the ion trap were adjusted to optimize S/N including; max 
injection time, collision induced dissociation (CID) intensity, and ion isolation width.  For 
testing of the optimization parameters, a 50 nM standard mix was made by diluting stock 
solutions of each eicosanoid in Ringer’s solution.  It was assumed that each setting was 
independent from one another and therefore each was optimized separately on different 
days.  Max injection time was found to be optimum around 400 milliseconds.  Shorter 
injection times lead to increased noise and higher detection limits (trace smoothing with 
boxcar averaging did not provide better signal to noise than longer injection time).  The 
optimum collision energy for each compound was found to be between 30 and 40 units.  
Finally, an isolation width of about 3.0 Da afforded the best S/N.   
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Figure 4.4: CID spectrum for 6-ketoPGF, precursor ion 369 m/z 
 
  
100 120 140 160 180 200 220 240 260 280 300 320 340 360
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
351.2
333.2
287.0
315.2
309.0
102 
 
 
 
 
 
Figure 4.5: CID spectrum for TXB, precursor ion 369 m/z 
  
100 120 140 160 180 200 220 240 260 280 300 320 340 360
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
195.0
325.1
169.0
287.1
351.1309.0
333.1
103 
 
 
 
 
 
Figure 4.6: CID spectrum for 8-isoPGF, precursor ion 353 m/z 
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Figure 4.7: CID spectrum for PGF, precursor ion 353 m/z 
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Figure 4.8: CID spectrum for PGE, precursor ion 351 m/z 
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Figure 4.9: CID spectrum for PGD, precursor ion 351 m/z 
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Figure 4.10: CID spectrum for LTB, precursor ion 335 m/z 
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Figure 4.11: Extracted ion chromatograms of 10 nM standards for each eicosanoid.  MS 
conditions were optimum for each standard 
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Each scan was set with the optimal settings for its respective analyte, and Figure 
4.11 is the resulting extracted ion chromatograms of 10 nM standards under these 
optimal conditions.  The limits of detection (S/N=3) was about 1 nM (~1.5 pg) for each 
prostaglandin and 5 nM (~8 pg) for LTB.  These detection limits are not as good as 
immunoassays (fg/mL) [4, 10], but they are similar to other LC/MS methods [12, 13]. 
4.5 Validation 
4.5.1 Ionization Suppression 
 The high salt concentration of microdialysis samples can lead to ionization 
suppression during LC-MS analysis.  During flow-injection analysis and LC-MS modes 
using negative ionization mode, molecular ions of [M-H]- and [M+Cl-]- were observed.  To 
evaluate ionization suppression vs. elution time, two gradients were employed one 
where the majority of analytes eluted before 6 min and the other where all analytes 
eluted after 6 minutes.  A 1 µM mixture of standards was run under each condition and 
peak areas were used to determine if elution time effected ionization suppression 
(Figure 4.12).  The peak areas of analytes with the early eluting gradient were 
decreased compared to those of the longer retention, but this difference was not 
significant.  With no distinct advantage to longer retention of the analytes the early 
elution gradient was chosen because it gave the best peak resolution.   
 To test the effect of ionization suppression, two sets of 50 nM standards were 
made; one in Ringer’s solution and one in nanopure water.  Both sets were injected 
repeatedly (n=5) with standards in water first to avoid salt carryover.  All the analytes 
except LTB were statistically (p<0.001) different between water and Ringer’s solution 
(Figure 4.13).  Standards prepared in Ringer’s solution had a decrease in signal 
between 12-21% compared to standards prepared in water.   
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Figure 4.12: Total ion chromatograms (with gradient profiles) of 1 µM eicosanoid 
mixtures in Ringer’s solution to examine the effects of ionization suppression with elution 
time 
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Figure 4.13: Ionization depression. Average peak areas of standards diluted in water 
and Ringer’s solution (n=5).  Only LTB was not statistically different between the two 
matrices, for all others, p<0.001. 
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4.5.2 Reproducibility 
 To determine intra-day reproducibility, a 100 nM standard was injected 
repeatedly throughout a day (n=7) (Table 4.2).  Solutions of 1000 and 10 nM were also 
injected repeatedly and there appeared to be no concentration dependence on peak 
elution or area.  For inter-day reproducibility, a 100 nM standard mixture was made and 
injected repeatedly (n=4) on four separate days (Table 4.3).  Again, solutions of 1000 
and 10 nM were also made and injected repeatedly.  It should be noted the difference 
between the intra- and inter-day reproducibility was due to adjustments to the system 
parameters.  Between the two experiments the LC and MS settings were adjusted in 
order to decrease run time and improve limits of detection.   
 A freeze-thaw experiment was performed where a 100 µM standard mixture was 
made in Ringer’s solution and aliquoted into separate microcentrifuge tubes to be stored 
at -20 °C for zero, one, and two days.  There was an observable decrease in response 
after the standard mixture had been frozen (Figure 4.14A); this was not the case when 
standards were diluted in water.  It was believed that the high salt concentration from the 
Ringer’s solution caused the eicosanoids to fall out of solution.   
In an attempt to prevent this problem, standards were diluted in Ringer’s solution 
containing 1 mM hydroxylpropyl-β-cyclodextrin.  As previously performed, a 100 µM 
mixture (with 1 mM cyclodextrin) was made and aliquoted into separate microcentrifuge 
tubes and frozen.  The decrease in response from freezing was alleviated with 
cyclodextrin; however, there was still a significant decrease for some of the eicosanoids 
(Figure 4.14B).  Because of this drop in response (both with and without cyclodextrin) all 
samples collected from either in vitro or in vivo were analyzed on the day collected and 
not frozen.   
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 Time   Peak Area  
 Avg ± STD CV (%)  Avg ± STD CV (%) 
6-Keto 3.01 ± 0.02 0.8  5300 ± 100 2 
TXB 4.12 ± 0.01 0.3  8100 ± 300 4 
8-Iso 4.09 ± 0.01 0.3  8200 ± 200 2 
PGF 4.66 ± 0.01 0.3  6300 ± 200 3 
PGE 5.104 ± 0.008 0.1  19200 ± 200 0.8 
PGD 5.52 ± 0.01 0.3  11600 ± 200 2 
LTB 8.736 ± 0.005 0.06  16500 ± 900 5 
 
Table 4.2: Intra-day reproducibility of retention times and peak areas for a 100 nM 
standard mixture of the seven eicosanoids (n=7). 
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 Time   Peak Area  
 Avg ± STD CV (%)  Avg ± STD CV (%) 
6-Keto 3.11 ± 0.03 1  6600 ± 400 6 
TXB 4.62 ± 0.05 1  8800 ± 600 7 
8-Iso 4.57 ± 0.05 1  9500 ± 500 5 
PGF 5.42 ± 0.05 1  7900 ± 500 6 
PGE 6.05 ± 0.06 0.9  25000 ± 2000 8 
PGD 6.65 ± 0.06 0.9  13000 ± 1000 8 
LTB 9.73 ± 0.02 0.2  14000 ± 2000 12 
 
Table 4.3: Inter-day reproducibility of retention times and peak areas of a 100 nM 
standard mixture of the seven eicosanoids (4 days, n=14) 
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Figure 4.14: Freeze-thaw data comparing 100 µM standards in Ringer’s solution (A) and 
in Ringer’s solution with 1 mM hydroxypropyl-β-cyclodextrin (B).   
  
0
10000
20000
30000
40000
50000
60000
6-keto TXB 8-iso PGF PGE PGD LTB
Day 0 Day 1 Day 2
0
10000
20000
30000
40000
50000
60000
70000
6-keto TXB 8-iso PGF PGE PGD LTB
Day 0 Day 1 Day 2
A
B
116 
 
4.6 Microdialysis 
4.6.1 In Vitro Sample Switching 
 All the prostaglandins demonstrated good recoveries when switching the probe 
between standard solutions.  LTB, however, had delayed responses compared to the 
prostaglandins when switching the probe between the sets of solutions (Figure 4.15).  
These data would indicate that LTB has some type of interaction with the probe.  
Previous reports of the effects of various membrane materials on leukotriene recovery 
showed that the more hydrophobic membranes (such as poly(arylene ether sulfone) 
used here) had lower mass transfer coefficients than the hydrophilic membranes [24].  
The delay in response from sample switching seen with LTB is most likely due to 
adsorption to the membrane surface.  Table 4.4 shows the recoveries for each 
compound during the specified solution, and these results are comparable to previous 
reports [24, 25] 
4.6.2 In Vivo 3-MPA Local Dosing 
 The 3-MPA local dosing model from Chapter 3 was used in order to correlate to 
the MDA results.  An MS1 single ion monitoring (SIM) scan of 105 m/z [M-H]- was added 
to the LC-MS method in order to detect 3-MPA in the dialysate samples.  Similar to 
previous work in our laboratory [26], 3-MPA delivery reached a steady state during the 
last 30 minutes of dosing, then had an exponential decay after dosing was terminated 
(Figure 4.16).  The average total delivery of 3-MPA to the hippocampus was 39.0 ± 0.8 
µg (n=3) as determined by subtracting the mass in the perfusate from the mass in the 
dialysate for each point during delivery.   
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Figure 4.15: Time plots of in vitro sampling switching experiment comparing 6-keto (-  -) 
and LTB (-  -).  Each box represents time frame when the microdialysis probe was in 50 
nM standard solution, for all other time points the probe was in Ringer’s solution.  Note 
the time delay in LTB reaching zero detection between solutions.   
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Sample 
Vial 
6-keto TXB 8-Iso PGF PGE PGD LTB 
1st 50 8.3 ± 
0.6 
12.7 ± 
0.9 
13 ± 1 14.9 ± 
0.7 
17 ± 1 24 ± 1 40 ± 10 
1st 100 8.7 ± 
0.5 
12 ± 1 12.3 ± 
0.7 
14.3 ± 
0.6 
19.3 ± 
0.4 
22 ± 1 33 ± 1 
2nd 50 7.3 ± 
0.5 
12.2 ± 
0.4 
11.2 ± 
0.9 
12.4 ± 
0.6 
15.9 ± 
0.3 
22.9 ± 
0.7 
42 ± 2 
2nd 100 10.8 ± 
0.4 
16.8 ± 
0.9 
15.6 ± 
0.5 
18.4 ± 
0.6 
26 ± 2 30 ± 1 42 ± 4 
3rd 50 7.6 ± 
0.9 
13 ± 1 11 ± 1 13.8 ± 
0.9 
18.0 ± 
0.8 
26 ± 3 49 ± 5 
 
Table 4.4: Percent recoveries for eicosanoids during the sample switching in vitro 
experiment.  Averages and deviations are based the time intervals in each specified 
solution, excluding the first 10 minute sample. 
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Figure 4.16: Estimated concentration of 3-MPA in dialysate samples from the 
hippocampus (n=3).  Dosing started at the 10 minute time point and ended after the 50 
minute time point.   
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 Of the seven analytes, only four were detectable in basal samples; PGF, PGE, 
PGD and TXB.  Interestingly, 8-iso, the free radical byproduct from COX, was not 
detectable in any sample during the experiment and neither was LTB.  6-Keto was more 
difficult to detect (in part from its peak shape) and could be detected more sporadically 
than the other prostaglandins.  There was a decrease in all prostaglandins during 3-MPA 
dosing followed by a rebound back to basal for PGF and PGD and to elevated levels for 
TXB and PGE (Figure 4.17).  Patel et al. [25] observed increases in TXB (3 to 4 times 
basal) and 6-keto (2 times basal) in the hippocampus following 20 minutes of ischemia; 
however, there were no changes in 6-keto with either 8 or 12 minutes of ischemia.  The 
changes in TXB post 3-MPA dose seen here were similar to those from Patel et al.  The 
decrease of the four previously mentioned prostaglandins during 3-MPA dosing was 
quite unexpected considering the amount of MDA produced with this same model in the 
same region (Chapter 3). 
 A possible explanation for the noticeable decrease in the prostaglandins is that 
while dosing, there is such an enormous amount of excitotoxicity occurring that all the 
accessible lipids are being oxidized into secondary products such as MDA.  There have 
been reports of free radical products such as isoPGE and isoPGD (that were not studied 
here) to suggest other possible mechanisms that are independent of COX but still lead 
to the formation of prostaglandins [27, 28].   
 Another class of lipids termed the endocannabinoids, in particular 
arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG), are arachidonic 
acid ester derivatives released from phosphatidylinositol-4,5-biphosphate by 
phospholipase C [29].  Theses cannabinoids can still be metabolized by COX (similar to 
arachidonic acid) to produce oxidative prostaglandin esters which can further oxidize 
and breakdown into MDA [30].   
121 
 
 
 
 
 
Figure 4.17: Response of TXB (-   -), PGF (-  -), PGE (-  -) and PGD (-  -) to 3-MPA local 
dosing in the hippocampus CA3 region.  Solid bar represents 50 minutes of 3-MPA 
dosing. 
  
-60 -30 0 30 60 90 120 150 180 210 240 270
0
50
100
150
200
250
P
e
rc
e
n
t 
B
a
s
a
l
Time (min)
122 
 
 Toscano et al reported a decrease in GABA mediated inhibition with COX-2 
knockout mice compared to wild type [31].  This relationship indicates a protective 
mechanism within the hippocampus and could provide another explanation to the results 
seen here.  As stated in Chapter 3, GABA increased to a greater extent in the CA3 than 
CA1 regions with 3-MPA local dosing, and there is a higher localization of COX-2 in the 
CA3 than CA1.  It is possible then, that the decrease in prostaglandins observed during 
3-MPA dosing could be an effect of GABA suppressing COX activity.   
In another study, the same group observed increases in PGF2, TXB2, PGD2 and 
PGE2 one hour after i.p. injections of kainate or NMDA in COX-2 knockout mice versus 
wild type [32].   More interestingly though, they found that while seizure intensity 
between either the kainate or NMDA dosed mice were the same, the quantities of 
prostaglandins produced were not.  This demonstrates that the levels of prostaglandins 
correlate with neuronal damage and not the severity of the seizure [32]. 
 Studies have demonstrated the induction of COX-2 involves two mechanisms; a 
rapid response to tissue damage (within 1 hour) followed by an excitotoxicity induction 
from stimulation (about 4 hours) [33].  The results here may be an after effect of the 
initial damage caused by probe implantation and not only from 3-MPA dosing.  To 
determine if this is the case, experiments with a longer wait time before 3-MPA dosing or 
with awake-animals should be performed. 
4.7 Conclusion 
 Here the coupling of HPLC with mass spectrometry allowed for separation and 
detection of seven eicosanoids including two sets of stereoisomers.  Mass spectrometry 
is a powerful technique with a high degree of selectivity not afforded by traditional 
spectrometric methods and was best suited for the detection of eicosanoids.  This 
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method provided linearity over 3 orders of magnitude with detection limits of about 1 nM 
for prostaglandins and 5 nM for LTB.  The application of this method to microdialysis 
samples from local dosing of 3-MPA in the hippocampus CA3 region revealed 
unpredicted results.  During 3-MPA dosing, prostaglandins decreased compared to 
basal which is the opposite result as MDA from the same model.   
  
124 
 
4.8 References 
1. Phillis, J. W.; Horrocks, L. A.; Farooqui, A. A., Cyclooxygenases, lipoxygenases, 
and epoxygenases in CNS: Their role and involvement in neurological disorders. 
Brain Res. Rev. 2006, 52 (2), 201-243. 
2. Lazarewicz, J. W.; Salinska, E., N-Methyl-D-Aspartate-Evoked Release of 
Cyclooxygenase Products in Rabbit Hippocampus - An In-Vivo Microdialysis 
Study. J. Neurosci. Res. 1995, 40 (5), 660-666. 
3. Ma, T. C.; Zhu, X. Z., Effects of intrahippocampal infusion of interleukin-6 on 
passive avoidance and nitrite and prostaglandin levels in the hippocampus in 
rats. Arzneimittelforschung 2000, 50 (3), E227-E231. 
4. Pepicelli, O.; Fedele, E.; Berardi, M.; Raiteri, M.; Levi, G.; Greco, A.; Ajmone-Cat, 
M. A.; Minghetti, L., Cyclo-oxygenase-1 and-2 differently contribute to 
prostaglandin E-2 synthesis and lipid peroxidation after in vivo activation of N-
methyl-D-aspartate receptors in rat hippocampus. J. Neurochem. 2005, 93 (6), 
1561-1567. 
5. Chen, C.; Bazan, N. G., Lipid signaling: Sleep, synaptic plasticity, and 
neuroprotection. Prostaglandins Other Lipid Mediat. 2005, 77 (1-4), 65-76. 
6. Sang, N.; Chen, C., Lipid signaling and synaptic plasticity. Neuroscientist 2006, 
12 (5), 425-434. 
7. Ercegovac, M.; Jovic, N.; Simic, T.; Beslac-Bumbasirevic, L.; Sokic, D.; Djukic, 
T.; Savic-Radojevic, A.; Matic, M.; Mimic-Oka, J.; Pljesa-Ercegovac, M., 
Byproducts of protein, lipid and DNA oxidative damage and antioxidant enzyme 
activities in seizure. Seizure 2010, 19 (4), 205-210. 
8. Pepicelli, O.; Fedele, E.; Bonanno, G.; Raiteri, M.; Ajmone-Cat, M. A.; Greco, A.; 
Levi, G.; Minghetti, L., In vivo activation of N-methyl-D-aspartate receptors in the 
rat hippocampus increases prostaglandin E-2 extracellular levels and triggers 
lipid peroxidation through cyclooxygenase-mediated mechanisms. J. Neurochem. 
2002, 81 (5), 1028-1034. 
9. Yin, H. Y.; Havrilla, C. M.; Gao, L.; Morrow, J. D.; Porter, N. A., Mechanisms for 
the formation of isoprostane endoperoxides from arachidonic acid - "Dioxetane" 
intermediate versus beta-fragmentation of peroxyl radicals. J. Biol. Chem. 2003, 
278 (19), 16720-16725. 
10. Malmberg, A. B.; Yaksh, T. L., Cyclooxygenase Inhibition and the Spinal Release 
of Prostaglandin E(2) and Amino-Acids Evoked by Paw Formalin Injection - A 
Microdialysis Study in Unanesthetized Rats. J. Neurosci. 1995, 15 (4), 2768-
2776. 
11. Schneede, J.; Mortensen, J. H.; Kvalheim, G.; Ueland, P. M., Capillary Zone 
Electrophoresis with Laser-Induced Fluorescence Detection for Analysis of 
Methylmalonic Acid and other Short-Chain Dicarboxylic-Acids Derivatized with 1-
Pyrenyldiazomethane. J. Chromatogr. A 1994, 669 (1-2), 185-193. 
12. Masoodi, M.; Eiden, M.; Koulman, A.; Spaner, D.; Volmer, D. A., Comprehensive 
Lipidomics Analysis of Bioactive Lipids in Complex Regulatory Networks. Anal. 
Chem. 2010, 82 (19), 8176-8185. 
13. Schmidt, R.; Coste, O.; Geisslinger, G., LC-MS/MS-analysis of prostaglandin E-2 
and D-2 in microdialysis samples of rats. J. Chromatogr. B 2005, 826 (1-2), 188-
197. 
14. Dass, C., Principles and Practice of Biological Mass Spectrometry. John Wiley & 
Sons, Inc: New York, 2001. 
125 
 
15. Silverstein, R. M.; Webster, F. X., Spectrometric Identification of Organic 
Compounds. 6th ed.; Wiley & Sons, Inc: Hoboken, 1998. 
16. Cech, N. B.; Enke, C. G., Practical implications of some recent studies in 
electrospray ionization fundamentals. Mass Spectrom. Rev. 2001, 20 (6), 362-
387. 
17. Robb, D. B.; Covey, T. R.; Bruins, A. P., Atmospheric pressure photoionisation: 
An ionization method for liquid chromatography-mass spectrometry. Anal. Chem. 
2000, 72 (15), 3653-3659. 
18. Fenn, J. B.; Mann, M.; Meng, C. K.; Wong, S. F.; Whitehouse, C. M., 
Electrospray Ionization for Mass-Spectrometry of Large Biomolecules. Science 
1989, 246 (4926), 64-71. 
19. Smith, R. D.; Loo, J. A.; Edmonds, C. G.; Barinaga, C. J.; Udseth, H. R., New 
Developments in Biochemical Mass-Spectrometry - Electrospray Ionization. Anal. 
Chem. 1990, 62 (9), 882-899. 
20. Cappiello, A., Advances in LC-MS Instrumentation. Elsevier: Amsterdam, 2007; 
Vol. 72. 
21. Bredy, R.; Bernard, J.; Chen, L.; Montagne, G.; Li, B.; Martin, S., An introduction 
to the trapping of clusters with ion traps and electrostatic storage devices. J. 
Phys. B-At. Mol. Opt. Phys. 2009, 42 (15). 
22. Kitteringham, N. R.; Jenkins, R. E.; Lane, C. S.; Elliott, V. L.; Park, B. K., Multiple 
reaction monitoring for quantitative biomarker analysis in proteomics and 
metabolomics. J. Chromatogr. B 2009, 877 (13), 1229-1239. 
23. Scientific, T. Radial Ejection and Dual Detection on Thermo Scientific LTQ Series 
Linear Ion Trap Mass Spectrometers 2012, p. 1. 
http://www.thermoscientific.com/ecomm/servlet/techresource?storeId=11152&lan
gId=-
1&taxonomy=4&resourceId=89010&contentType=Product+Support+Bulletins&pr
oductId=11960637#. 
24. Sun, L.; Stenken, J. A., Improving microdialysis extraction efficiency of lipophilic 
eicosanoids. J. Pharm. Biomed. Anal. 2003, 33 (5), 1059-1071. 
25. Patel, P. M.; Drummond, J. C.; Mitchell, M. D.; Yaksh, T. L.; Cole, D. J., 
Eicosanoid Production in the Caudate-Nucleus and Dorsal Hippocampus After 
Forebrain Ischemia - A Microdialysis Study. J. Cereb. Blood Flow Metab. 1992, 
12 (1), 88-95. 
26. Mayer, A. Local Dosing in a 3-Mercaptopropionic Acid Chemically-Induced 
Epileptic Seizure Model with Microdialysis Sampling. University of Kansas, 
Lawrence, 2010. 
27. Brose, S. A.; Thuen, B. T.; Golovko, M. Y., LC/MS/MS method for analysis of E-2 
series prostaglandins and isoprostanes. J. Lipid Res. 2011, 52 (4), 850-859. 
28. Gao, L.; Zackert, W. E.; Hasford, J. J.; Danekis, M. E.; Milne, G. L.; Remmert, C.; 
Reese, J.; Yin, H. Y.; Tai, H. H.; Dey, S. K.; Porter, N. A.; Morrow, J. D., 
Formation of prostaglandins E-2 and D-2 via the isoprostane pathway - A 
mechanism for the generation of bioactive prostaglandins independent of 
cyclooxygenase. J. Biol. Chem. 2003, 278 (31), 28479-28489. 
29. Rouzer, C. A.; Marnett, L. J., Non-redundant functions of cyclooxygenases: 
Oxygenation of endocannabinoids. J. Biol. Chem. 2008, 283 (13), 8065-8069. 
30. Costa, B.; Conti, S.; Giagnoni, G.; Colleoni, M., Therapeutic effect of the 
endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: 
inhibition of nitric oxide and cyclo-oxygenase systems. Br. J. Pharmacol. 2002, 
137 (4), 413-420. 
126 
 
31. Toscano, C. D.; Ueda, Y.; Tomita, Y. A.; Vicini, S.; Bosetti, F., Altered GABAergic 
neurotransmission is associated with increased kainate-induced seizure in 
prostaglandin-endoperoxide synthase-2 deficient mice. Brain Res. Bull. 2008, 75 
(5), 598-609. 
32. Toscano, C. D.; Kingsley, P. J.; Marnett, L. J.; Bosetti, F., NMDA-induced seizure 
intensity is enhanced in COX-2 deficient mice. Neurotoxicology 2008, 29 (6), 
1114-1120. 
33. Adams, J.; CollacoMoraes, Y.; deBelleroche, J., Cyclooxygenase-2 induction in 
cerebral cortex: An intracellular response to synaptic excitation. J. Neurochem. 
1996, 66 (1), 6-13. 
 
 
 
127 
 
Chapter 5  
Conclusions and Future Directions 
5.1 Conclusions 
 Two analytical methods were developed to monitor lipid peroxidation in animal 
models of oxidative stress using microdialysis sampling.  First developed was a CE-
fluorescence method for the detection of MDA.  This method provided a range of 
linearity of over 2 orders of magnitude with LOD of 25 nM.  The second method was an 
LC-MS/MS method for the detection of seven products of the arachidonic acid cascade; 
6-ketoPGF1α, TXB2, 8-isoPGF2α, PGF2, PGE2, PGD2, and LTB4.  The method had a 
range of linearity of 3 orders of magnitude for all analytes with detection limits of around 
1nM.   
 These methods were applied to a focal seizure animal model previously used in 
our laboratory [1].  In this model, 3-MPA was dosed through the microdialysis probe for 
50 minutes directly into the CA3 or CA1 regions of the hippocampus.  3-MPA is an 
inhibitor of glutamate decarboxylase, preventing the synthesis of GABA from glutamate 
creating an excitatory state in the brain.  Excitotoxicity from glutamate can cause cell 
death and has been related to several disease states such as Alzheimer’s, Parkinson’s, 
and Amyotrophic Lateral Sclerosis [2]. 
 Shortly after the start of 3-MPA dosing there were increases in MDA ultimately 
reaching a maximum of 7 µM in the CA3 and 4 µM in the CA1 region at the end of the 10 
mM 3-MPA perfusion.  MDA began to decrease after dosing, but never returned to basal 
levels.  Dosing 1 and 0.1 mM 3-MPA also produced an increase in MDA although there 
was not a linear relationship between 3-MPA concentration and MDA production.  It was 
postulated that the difference in MDA between the two regions in the hippocampus was 
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due to greater localization of COX-2 in the CA3 than in the CA1.  COX-2 is the inducible 
isoform of COX catalyzing the synthesis of prostaglandins from arachidonic acid.  If 
there is more COX-2, then there is more oxidation of poly-unsaturated lipids leading to 
more MDA formation.    
 3-MPA local dosing also produced increases in glutamate and GABA in both 
regions of the hippocampus.  Interestingly, changes in glutamate were the same 
between regions while there was a greater increase in GABA in the CA3 than the CA1 
region.  This difference in GABA between regions was attributed to a greater number of 
GABAnergic neurons located about the CA3 region in the dentate gyrus.   
 The only arachidonic acid metabolites detected in the CA3 region were TXB, 
PGF, PGE and PGD.  During 3-MPA dosing, there was an unexpected decrease in all 
four prostaglandins.  It was postulated that this decrease was due to free radical attack 
on the prostaglandins as a result of the excitotoxicity from glutamate ultimately forming 
MDA in the process. 
 Although the exact mechanism to which lipid peroxidation occurs during 3-MPA 
local dosing is not yet fully understood, the degree of damage in the hippocampus has 
become more clear.  It is evident that both glutamate and GABA play key roles to the 
extent of peroxidation.  It has also become clear that lipid peroxidation occurs very 
rapidly during times of elevated glutamate and it is possible that this initial insult could 
have lasting effects on the structure and function of the hippocampus.  Furthermore, the 
observation of MDA never returning to basal levels is indicative of continuing oxidation 
long after the cessation of stress.  Lipid peroxidation plays a predominant role in 
oxidative stress events, and the ability to limit this type of damage could aid in the 
survival of tissue surrounding the area of insult.   
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5.2 Future Directions 
The next step for this project is to continue the evaluation of the aforementioned 
prostaglandins in the CA1 region of the hippocampus.  To further clarify the mechanisms 
associated here, modulating agents would be perfused.  For example, dosing of 
selective inhibitors for either COX or PLA through the probe could help determine if the 
increase in MDA observed resulted from of the oxidation of prostaglandin metabolism or 
release of unsaturated fatty acids.  Also, there have been reports of other isoprostanes 
related to PGE and PGD formed during oxidative stress [3].  These isoprostanes (8-
isoPGE and 8-isoPGD) were observed in liver and urine.  It would be interesting if either 
of these isoprostanes could be detectable in this 3-MPA model.   
Another interesting study would be to see if the hippocampus is communicating 
within itself during 3-MPA dosing.  In this experiment, two probes would be implanted, 
one in each region (the distance between implantation sites is large enough for both 
probes) and 3-MPA would then be dosed into one region at a time.  Of course 3-MPA 
would have to be monitored in both regions to determine if there was either diffusion 
through the brain causing a response or if it was from signaling between regions.  This 
may help elucidate the plausibility of the inhibitory surround theory [1], as well as the 
propagation of damage through the hippocampus. 
It is possible that the increase in glutamate and GABA observed could have been 
diminished from the anesthesia used, as ketamine is a known NMDA antagonist [4].  
Other reports have also demonstrated depressed glutamate stimulation with volatile 
anesthesia (i.e. isoflurane), disrupting NMDA transmission [5].  Previous work done in 
this laboratory showed differences between glutamate and GABA with local dosing of 3-
MPA in several regions of the brain [1].  It is possible that the anesthesia could have 
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mitigated the damage caused thereby lessening MDA formation.  Also, studies have 
demonstrated the generation of COX-2 involves two mechanisms: a rapid response to 
tissue damage (within 1 hour) followed by an excitotoxic induction from stimulation 
(about 4 hours) [6].  The results of MDA and the prostaglandins may be an after effect of 
the damage caused by probe implantation and the initial increase in COX-2 and not from 
the excitotoxicity of 3-MPA dosing.  Therefore awake-animal studies would be needed in 
order to exclude other possible mechanisms.   
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